Neuro Foundations

Study Notes

Table of Contents

1. [Neurotransmitters](#1-neurotransmitters)
2. 1.1 Definitions and Classification
3. 1.2 Serotonin (5-HT)
4. 1.3 Dopamine (DA)
5. 1.4 Norepinephrine (NE)
6. 1.5 GABA
7. 1.6 Glutamate
8. 1.7 Acetylcholine (ACh)
9. 1.8 Histamine
10. 1.9 Glycine
11. 1.10 Peptide Neurotransmitters
12. 1.11 Gaseous Neurotransmitters
13. 1.12 Endocannabinoids
14. 1.13 Master Comparison Table
15. [Neuroanatomy](#2-neuroanatomy)
16. 2.1 Frontal Lobe
17. 2.2 Basal Ganglia
18. 2.3 Limbic System
19. 2.4 Papez Circuit
20. 2.5 Thalamus
21. 2.6 Hypothalamus
22. 2.7 Other Structures of Psychiatric Relevance
23. [Sleep Physiology](#3-sleep-physiology)
24. 3.1 Sleep Architecture
25. 3.2 Sleep Cycles
26. 3.3 Neurochemistry of Sleep
27. 3.4 Circadian Rhythm
28. 3.5 Sleep Changes in Psychiatric Disorders
29. 3.6 Sleep Disorders Overview

1. NEUROTRANSMITTERS

1.1 Definitions and Classification

Neurotransmitter vs Neuromodulator

Swipe to compare →

Criteria for a Neurotransmitter (Dale's Criteria, modified)

1. Synthesized in the presynaptic neuron
2. Stored in synaptic vesicles
3. Released in response to depolarization (Ca2+-dependent)
4. Acts on specific postsynaptic receptors
5. Has a mechanism for termination (reuptake, enzymatic degradation, diffusion)
6. Exogenous application mimics endogenous effect

Classification of Neurotransmitters

Signal Transduction: Two Major Receptor Classes

1.2 Serotonin (5-Hydroxytryptamine, 5-HT)

Synthesis Pathway

Brain Distribution

• Cell bodies: Raphe nuclei (dorsal and median) in the brainstem
• Dorsal raphe → cortex, basal ganglia, limbic system (cognition, mood, anxiety)
• Median raphe → hippocampus, septum (memory, theta rhythm)
• Serotonergic neurons project to virtually every brain region
• Ascending projections: cortex, limbic, hypothalamus
• Descending projections: spinal cord (pain modulation)

Receptor Subtypes

There are 7 families (5-HT1 through 5-HT7) with at least 14 subtypes. Key ones for psychiatry:

Termination of Signal

• Reuptake: SERT (serotonin transporter), target of SSRIs, SNRIs, TCAs
• Degradation: MAO-A (monoamine oxidase A) → 5-HIAA
• SERT is coded by the SLC6A4 gene. The short (s) allele of the 5-HTTLPR polymorphism → reduced SERT expression → historically linked to stress sensitivity (Caspi et al., 2003), though meta-analyses have been mixed

Clinical Relevance Summary

Serotonin Syndrome

Cause: Excess serotonergic activity, usually from drug combinations (SSRI + MAOI, SSRI + tramadol, SSRI + linezolid, SSRI + St. John's wort).

Triad:

1. Neuromuscular: Clonus (especially lower extremity), hyperreflexia, rigidity, tremor
2. Autonomic: Hyperthermia, diaphoresis, tachycardia, hypertension, diarrhea
3. Mental status: Agitation, confusion, hypomania

Distinguishing features:

• Clonus is the hallmark (especially ocular clonus)
• Onset within 24 hours of causative agent
• Resolves within 24-72 hours after discontinuation

Differentiation from NMS:

1.3 Dopamine (DA)

Synthesis Pathway

The Four Classical Dopamine Pathways

Fifth pathway (less commonly tested):

• Mesolimbic-mesocortical overlap with thalamus: VTA → thalamic nuclei, contributes to filtering sensory information

Dopamine Receptors

Termination of Signal

• Reuptake: DAT (dopamine transporter), target of cocaine (blockade), amphetamine (reversal + efflux)
• Degradation:
• MAO-A and MAO-B → DOPAC
• COMT (catechol-O-methyltransferase) → 3-MT, then → HVA
• HVA (homovanillic acid) = final metabolite measured in CSF/plasma
• COMT is especially important in PFC where DAT density is low
• Val158Met polymorphism: Val/Val = high COMT activity = lower PFC dopamine = potentially worse cognition; Met/Met = low COMT = higher PFC dopamine

Clinical Relevance Summary

1.4 Norepinephrine (NE)

Synthesis

Same pathway as dopamine, one additional step:

• DβH (dopamine β-hydroxylase) is the distinguishing enzyme for NE neurons
• DβH is a copper-containing enzyme, disulfiram inhibits it

Brain Distribution

• Cell bodies: Locus coeruleus (LC) in the dorsal pons, the SOLE source of NE for the neocortex
• LC contains ~50,000 neurons bilaterally but projects to entire cortex, hippocampus, thalamus, cerebellum, spinal cord
• Function of LC: Arousal, vigilance, attention, stress response, fight-or-flight
• LC fires tonically during wakefulness, less during SWS, silent during REM

Receptors

Termination

• Reuptake: NET (norepinephrine transporter), target of SNRIs, TCAs, atomoxetine, bupropion (weak)
• Degradation: MAO-A → MHPG (3-methoxy-4-hydroxyphenylglycol), primary CNS metabolite
• COMT also degrades NE peripherally → VMA (vanillylmandelic acid), normetanephrine

Clinical Relevance Summary

1.5 GABA (Gamma-Aminobutyric Acid)

Synthesis

• GAD is the rate-limiting enzyme and requires pyridoxal phosphate (B6) as cofactor
• Two isoforms: GAD65 (synaptic terminals) and GAD67 (cell bodies)
• B6 deficiency → ↓ GABA → seizures (e.g., in isoniazid overdose, treat with IV pyridoxine)
• GAD antibodies found in: stiff-person syndrome, type 1 diabetes, autoimmune epilepsy, cerebellar ataxia

Distribution

• The most abundant inhibitory neurotransmitter in the CNS (~30-40% of all synapses are GABAergic)
• Found throughout the brain, cortex, hippocampus, thalamus, basal ganglia, cerebellum, brainstem
• GABAergic interneurons regulate cortical circuits, dysfunction implicated in schizophrenia

Receptors

GABA-A (Ionotropic)

• Structure: Pentameric ligand-gated chloride (Cl-) channel
• Most common composition: 2α + 2β + 1γ subunit
• Cl- influx → membrane hyperpolarization → inhibition
• Multiple binding sites on the same receptor complex:

Subunit specificity:

• α1 → sedation, amnesia, anticonvulsant (targeted by zolpidem, Z-drugs)
• α2/α3 → anxiolysis, muscle relaxation
• α5 → memory, cognition (inverse agonists may enhance cognition)
• BZDs bind at α1/2/3/5 containing receptors (NOT α4 or α6)

GABA-B (Metabotropic)

• Structure: GPCR (Gi-coupled)
• Mechanism: ↑ K+ conductance (postsynaptic) and ↓ Ca2+ entry (presynaptic) → inhibition
• Agonist: Baclofen (used for spasticity, alcohol withdrawal, intractable hiccups)
• Clinical: GABA-B involved in absence seizures (thalamocortical circuits), alcohol dependence, GHB mechanism

GABA-C (sometimes classified as GABA-A-rho)

• Ionotropic, found primarily in retina
• Insensitive to BZDs and barbiturates
• Minor psychiatric relevance

Termination

• Reuptake: GAT-1 (GABA transporter 1), target of tiagabine (anticonvulsant)
• Degradation: GABA-T (GABA transaminase) → succinic semialdehyde → succinic acid (enters Krebs cycle)
• Vigabatrin = irreversible GABA-T inhibitor → ↑ GABA. Used in infantile spasms. Risk: visual field defects

Clinical Relevance Summary

1.6 Glutamate

Synthesis

• Also derived from α-ketoglutarate (Krebs cycle) via transamination
• Glutamate-glutamine cycle: Glutamate released into synapse → taken up by astrocytes → converted to glutamine by glutamine synthetase → shuttled back to neuron → converted back to glutamate

Distribution

• The most abundant excitatory neurotransmitter in the CNS (~50-60% of all synapses)
• Present in virtually every brain region
• Major excitatory neurotransmitter of cortical pyramidal neurons

Receptors

Ionotropic (fast excitatory transmission)

Metabotropic (mGluR1-8)

NMDA Receptor in Detail

Unique properties:

1. Voltage-dependent Mg2+ block, at resting potential, Mg2+ plugs the channel. Requires prior AMPA-mediated depolarization to remove Mg2+ → then NMDA opens
2. Co-agonist requirement, needs glutamate at glutamate site AND glycine/D-serine at glycine site
3. Ca2+ permeability, allows Ca2+ influx → activates CaMKII, CREB → gene transcription → synaptic plasticity (LTP)
4. Multiple modulatory sites: polyamine site, Zn2+ site, phencyclidine site (where ketamine/PCP bind)

Excitotoxicity

• Excessive glutamate → prolonged NMDA activation → massive Ca2+ influx → activates destructive enzymes (calpains, endonucleases, lipases) → cell death
• Implicated in: stroke, TBI, neurodegenerative diseases (ALS, Alzheimer's, Huntington's), status epilepticus, hepatic encephalopathy

The Glutamate Hypothesis of Schizophrenia

• Origin: PCP and ketamine (NMDA antagonists) produce schizophrenia-like symptoms INCLUDING negative and cognitive symptoms, something dopaminergic agents don't fully explain
• Hypothesis: NMDA receptor hypofunction on GABAergic interneurons → loss of inhibition on glutamatergic pyramidal neurons → downstream excess glutamate in some regions → excess dopamine in mesolimbic pathway (positive symptoms) AND deficit in mesocortical pathway (negative/cognitive symptoms)
• Integrates with dopamine hypothesis rather than replacing it
• Therapeutic implications: Glycine site agonists (D-serine, glycine, D-cycloserine) as adjuncts in schizophrenia, modest evidence

Ketamine's Antidepressant Mechanism

1. Blocks NMDA receptors on GABAergic interneurons (preferentially)
2. → Disinhibition of glutamatergic neurons → glutamate burst
3. → Activates AMPA receptors → BDNF release → mTOR activation
4. → Rapid synaptogenesis in PFC (within hours)
5. → Antidepressant effect within hours (vs weeks for SSRIs)

Clinical Relevance Summary

1.7 Acetylcholine (ACh)

Synthesis

• ChAT is the synthetic enzyme and marker for cholinergic neurons
• Choline is taken up by a high-affinity choline transporter (rate-limiting)
• Degradation: AChE (acetylcholinesterase) rapidly hydrolyzes ACh in the synaptic cleft

Brain Distribution

Two major cholinergic systems:

Receptors

Clinical Relevance Summary

1.8 Histamine

Synthesis

• Degradation: histamine N-methyltransferase (HMT) → methylhistamine → MAO-B → methylimidazoleacetic acid

Brain Distribution

• Cell bodies: Tuberomammillary nucleus (TMN) of the posterior hypothalamus, sole source of histaminergic neurons in brain
• Projects diffusely to entire cortex, similar to NE and 5-HT

Receptors

1.9 Glycine

• Primary inhibitory NT in the spinal cord and brainstem (GABA is the primary inhibitory NT in the brain)
• Acts on glycine receptors (ionotropic Cl- channels), strychnine is a glycine receptor antagonist → convulsions
• Also a co-agonist at the NMDA receptor (glycine site), this dual role is important
• D-serine is the primary endogenous co-agonist at the NMDA glycine site in the forebrain
• D-cycloserine is a partial agonist at this site, used as adjunct in exposure therapy for anxiety disorders (enhances extinction learning)
• Glycine transporter (GlyT1): Reuptakes glycine near NMDA receptors. GlyT1 inhibitors (sarcosine, bitopertin) increase glycine at NMDA receptors, investigated for schizophrenia

1.10 Peptide Neurotransmitters

Key Neuropeptides in Psychiatry

1.11 Gaseous Neurotransmitters

Nitric Oxide (NO)

• Synthesis: L-arginine → (nitric oxide synthase, NOS) → NO + citrulline
• nNOS (neuronal), eNOS (endothelial), iNOS (inducible/immune)
• Mechanism: NOT stored in vesicles. Synthesized on demand. Freely diffuses across membranes. Acts on soluble guanylyl cyclase → ↑ cGMP
• Functions: Retrograde signaling (postsynaptic → presynaptic), vasodilation, LTP, penile erection
• Clinical relevance:
• PDE5 inhibitors (sildenafil) work by preventing cGMP breakdown (downstream of NO)
• NO involved in NMDA-mediated neurotoxicity
• Role in migraine pathophysiology

Carbon Monoxide (CO)

• Produced by heme oxygenase (HO-1, HO-2) from heme breakdown
• Similar mechanism to NO (activates guanylyl cyclase)
• Less studied than NO in psychiatry

1.12 Endocannabinoids

The Endocannabinoid System

Clinical Relevance

1.13 Master Comparison Table

2. NEUROANATOMY

2.1 Frontal Lobe

The frontal lobe constitutes ~1/3 of the cortical surface. It is the seat of executive function, personality, social behavior, and motor planning. The prefrontal cortex (PFC) is the most anterior portion, anterior to the motor and premotor areas.

Prefrontal Cortex Subdivisions

Frontal Lobe Syndromes: The Classic Three

Key Clinical Correlates of Frontal Lobe

Laterality of Frontal Function

2.2 Basal Ganglia

Components

Mnemonic for dorsal striatum: Caudate + Putamen = Striatum (because of the striped appearance from gray and white matter bundles crossing)

Basal Ganglia Circuits (Alexander & Crutcher model)

All circuits follow the same basic loop: Cortex → Striatum → Pallidum/SN → Thalamus → Cortex

Direct vs Indirect Pathway

Disorders of the Basal Ganglia

2.3 Limbic System

Core Structures

Amygdala

• Location: Anterior medial temporal lobe, anterior to hippocampus
• Nuclei: Basolateral (sensory input processing), central (output to hypothalamus and brainstem), corticomedial (olfaction)
• Functions:
• Fear conditioning, learning to associate a neutral stimulus with danger (Pavlovian fear conditioning)
• Emotional memory, strengthens memory consolidation for emotionally charged events (via modulation of hippocampal function)
• Threat detection, rapid, below-conscious evaluation of potential danger
• Social cognition, reading facial expressions (especially fear and anger)

Connections:

• Receives input from all sensory modalities
• Outputs to: hypothalamus (autonomic responses), PAG (behavioral responses), basal forebrain (arousal), cortex (conscious awareness)
• Two pathways for fear: (1) Thalamus → amygdala (fast, crude, "low road," LeDoux) and (2) Thalamus → cortex → amygdala (slow, precise, "high road")

Clinical relevance:

Hippocampus

• Location: Medial temporal lobe, floor of inferior horn of lateral ventricle
• Structure: Archicortex with 3 layers (vs 6 in neocortex). CA1-CA4 regions, dentate gyrus, subiculum
• Functions:
• Declarative/explicit memory, episodic (events) and semantic (facts)
• Spatial navigation, place cells (O'Keefe, Nobel Prize 2014)
• Memory consolidation, transfers short-term to long-term memory (to neocortex during sleep)
• Contextual fear conditioning, "where" the danger was
• Neurogenesis, dentate gyrus is one of two sites of adult neurogenesis (the other being the subventricular zone → olfactory bulb)

LTP (Long-Term Potentiation):

• Discovered in hippocampus (Bliss & Lomo, 1973)
• NMDA receptor-dependent (requires coincidence of presynaptic glutamate release AND postsynaptic depolarization)
• Considered the cellular basis of learning and memory
• Blocked by NMDA antagonists → amnesia

Clinical relevance:

Other Limbic Structures

2.4 Papez Circuit

Components and Flow

Key Points

• Proposed by James Papez (1937) as the circuit of emotion
• Now understood as primarily a memory circuit rather than a purely emotional circuit
• Damage at any point in the circuit → memory deficits (especially anterograde amnesia)

Clinical Correlates by Lesion Site

Yakovlev Circuit (the "other" limbic circuit)

Complements Papez, more related to emotion and behavior:

• Lesions → emotional dysregulation, disinhibition
• Relevant to psychopathy, OFC syndromes

2.5 Thalamus

Overview

• "Gateway to the cortex", nearly all sensory information relays through the thalamus (except olfaction, which goes directly to cortex)
• Reciprocal connections with cortex, thalamocortical and corticothalamic loops
• Two main nuclei types: specific (relay nuclei, point-to-point) and nonspecific (diffuse modulatory)

Key Thalamic Nuclei for Psychiatry

Thalamus in Psychiatric Conditions

2.6 Hypothalamus

Overview

• Small (4g) but controls virtually all homeostatic functions
• Forms the floor and lateral walls of the third ventricle
• Connected to the pituitary via the infundibulum (pituitary stalk)

Major Nuclei and Functions

The HPA Axis

HPA Axis in Psychiatric Disorders:

2.7 Other Structures of Psychiatric Relevance

Temporal Lobe

Parietal Lobe

Cerebellum

• Beyond motor: Now recognized to contribute to cognition, emotion, and language
• Cerebellar cognitive affective syndrome (Schmahmann): Executive dysfunction, visuospatial deficits, language issues, personality change (blunted affect or disinhibition)
• Cerebellar abnormalities found in autism, schizophrenia, ADHD

Brainstem Nuclei Summary

3. SLEEP PHYSIOLOGY

3.1 Sleep Architecture

Overview

Sleep is divided into NREM (Non-Rapid Eye Movement) and REM (Rapid Eye Movement) sleep. They alternate in cycles across the night.

NREM Sleep Stages

REM Sleep

Key Differences: NREM vs REM

3.2 Sleep Cycles

The 90-Minute Ultradian Rhythm

• Each sleep cycle = NREM (N1 → N2 → N3 → N2) → REM
• Duration: ~90-110 minutes per cycle
• Typically 4-6 cycles per night

How Cycles Change Across the Night

Sleep Architecture Across the Lifespan

3.3 Neurochemistry of Sleep

The Two-Process Model (Borbely, 1982)

Wake-Promoting Systems

Sleep-Promoting Systems

The Flip-Flop Switch Model (Saper)

The sleep-wake transition is like a flip-flop switch, it's either in one state or the other, with rapid transitions between them:

• Orexin stabilizes the switch in the WAKE position, without it, the switch flips uncontrollably → narcolepsy (sudden sleep attacks, cataplexy)
• This explains why we have discrete wake and sleep states (not a gradual continuum)

Neurochemistry of REM Sleep

REM-ON neurons:

• Cholinergic neurons in PPN and LDT (brainstem)
• Glutamatergic neurons in sublaterodorsal nucleus (SLD) → generate muscle atonia via glycine/GABA

REM-OFF neurons:

• Noradrenergic (LC) and serotonergic (raphe) neurons
• Silence during REM → permits REM

REM-promoting mechanism:

• During NREM, REM pressure builds (acetylcholine accumulates)
• LC and raphe gradually decrease firing → threshold reached → PPN/LDT disinhibited → REM onset
• REM lasts until NE/5-HT neurons resume firing → terminate REM

Key Sleep Neurochemistry Summary Table

3.4 Circadian Rhythm

The Master Clock: Suprachiasmatic Nucleus (SCN)

• Located in the anterior hypothalamus, above the optic chiasm
• Contains ~20,000 neurons with endogenous ~24.2-hour rhythm
• Entrainment (zeitgebers): Light is the most powerful. Others: social cues, meals, exercise, temperature
• Light pathway: Retina (intrinsically photosensitive retinal ganglion cells, ipRGCs, containing melanopsin, most sensitive to blue light ~480 nm) → retinohypothalamic tract → SCN

Molecular Clock

Transcription-translation feedback loops (TTFL):

Additional loop: REV-ERBα/RORα regulate BMAL1 transcription

Melatonin Pathway

Circadian Disruption in Psychiatry

3.5 Sleep Changes in Psychiatric Disorders

Depression

Mania

Anxiety Disorders

Schizophrenia

Other Conditions

Summary Table: Sleep Stage Changes by Disorder

3.6 Sleep Disorders Overview

Insomnia

Narcolepsy

Parasomnias

NREM Parasomnias (Disorders of Arousal)

REM Parasomnias

Sleep Terrors vs Nightmares

Obstructive Sleep Apnea (OSA)

Restless Legs Syndrome (RLS) / Willis-Ekbom Disease

Circadian Rhythm Sleep-Wake Disorders

Other Sleep Disorders

Pharmacology and Sleep: Quick Reference

High-Yield Exam Pearls

Neurotransmitters

Neuroanatomy

Sleep

Document prepared for NB-01: P1-Neuro-Foundations. Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Stahl's Essential Psychopharmacology, Kandel's Principles of Neural Science, Sadock's Synopsis of Psychiatry. For PG exams MD Psychiatry exit examination preparation.

Model Answers

Document Type: Model Answer Bank

Sources: Kaplan & Sadock (14th ed.), Stahl's Essential Psychopharmacology (5th ed.), PG exams Master Compilation, PG exams PYQ Bank

SECTION A: NEUROTRANSMITTER PYQs (Q1–Q15)

Q1: "Define neurotransmitters. How do they differ from neuromodulators? Name excitatory neurotransmitters and describe any one in detail.": 10 marks

A. Definition of Neurotransmitters [2]

A neurotransmitter is a chemical substance that satisfies the following criteria:

1. Synthesized in the presynaptic neuron
2. Stored in synaptic vesicles at the nerve terminal
3. Released in a calcium-dependent manner upon depolarization
4. Acts on specific postsynaptic receptors to produce a biological effect
5. Has a mechanism for inactivation (reuptake, enzymatic degradation, or diffusion)
6. Can be mimicked by exogenous application and blocked by specific antagonists

B. Neurotransmitters vs. Neuromodulators: Key Differences [3]

Swipe to compare →

C. Excitatory Neurotransmitters [2]

• Glutamate (principal excitatory NT in the CNS)
• Aspartate
• Acetylcholine (at nicotinic receptors)
• Norepinephrine (at certain receptors)
• Substance P
• Histamine (at certain receptors)

D. Glutamate: Detailed Description [3]

Synthesis:

• Synthesized from glutamine by the enzyme glutaminase in presynaptic terminals
• Also derived from the Krebs cycle (alpha-ketoglutarate via transamination)
• The glutamate-glutamine cycle between neurons and astrocytes is critical for recycling

Receptors (4 types):

Inactivation:

• Reuptake by excitatory amino acid transporters (EAATs) on neurons and astrocytes
• In astrocytes: converted back to glutamine by glutamine synthetase

Clinical Relevance:

• Excitotoxicity: Excessive glutamate → sustained Ca²⁺ influx → neuronal death. Implicated in stroke, traumatic brain injury, neurodegenerative diseases
• Schizophrenia: NMDA receptor hypofunction hypothesis, PCP and ketamine (NMDA antagonists) produce psychotic symptoms. Explains negative and cognitive symptoms better than the dopamine hypothesis alone
• Depression: Ketamine (NMDA antagonist) produces rapid antidepressant effects; esketamine (Spravato) approved for treatment-resistant depression
• Epilepsy: Glutamate excess → seizure propagation
• Alzheimer's disease: Memantine (NMDA antagonist) used therapeutically to reduce excitotoxicity
• Anxiety: mGluR modulators under investigation as novel anxiolytics

Diagram description: Draw the glutamate-glutamine cycle, presynaptic neuron (glutaminase converts glutamine → glutamate → packaged into vesicles by VGLUT → released → acts on NMDA/AMPA/Kainate/mGluR on postsynaptic neuron) → taken up by astrocyte (EAAT) → glutamine synthetase converts glutamate → glutamine → shuttled back to neuron.

(See also Q3 for amino acid neurotransmitters, Q9 for glutamate in depression)

Q2: "Neurotransmitters. Describe role of dopamine in Psychiatry.": 10 marks

A. Overview of Neurotransmitters [3]

Classification:

B. Dopamine in Psychiatry [7]

Synthesis pathway:

Tyrosine → (tyrosine hydroxylase, rate-limiting) → L-DOPA → (DOPA decarboxylase) → Dopamine

Degradation: MAO-B and COMT → HVA (homovanillic acid, measured in CSF)

Dopamine Receptors:

The 4 Major Dopaminergic Pathways:

(+) 5th pathway: Thalamic pathway (multiple origins → thalamus), involved in arousal, sleep-wake regulation.

Role in Specific Psychiatric Disorders:

• Schizophrenia: Dopamine hypothesis, mesolimbic hyperactivity (positive symptoms), mesocortical hypoactivity (negative/cognitive symptoms). All effective antipsychotics block D2 receptors (minimum 60–65% occupancy for efficacy, >80% → EPS).
• Bipolar disorder: Dopamine dysregulation contributes to both mania (↑ DA) and depression (↓ DA).
• Depression: Anhedonia, psychomotor retardation linked to mesocortical/mesolimbic DA deficit. Bupropion (NDRI) works via dopamine.
• ADHD: Mesocortical dopamine deficit in prefrontal cortex. Methylphenidate and amphetamines increase DA.
• Substance use disorders: All drugs of abuse converge on mesolimbic pathway → dopamine surge in nucleus accumbens.
• OCD: Dopamine augmentation (aripiprazole) helps treatment-resistant OCD.
• Tourette syndrome: Dopamine hyperactivity in basal ganglia. Responds to D2 blockers.

Diagram description: Draw the 4 dopaminergic pathways, show VTA projecting to nucleus accumbens (mesolimbic) and PFC (mesocortical); substantia nigra projecting to striatum (nigrostriatal); arcuate nucleus projecting to pituitary (tuberoinfundibular). Label each with function and disorder.

(See Q5, Q6, Q11 for expanded dopamine discussions)

Q3: "Amino Acid neurotransmitters.": 10 marks

A. Introduction [1]

Amino acid neurotransmitters are the most abundant neurotransmitters in the CNS. They mediate fast synaptic transmission (unlike monoamines which are slower/modulatory).

Four main amino acid NTs:

• Excitatory: Glutamate, Aspartate
• Inhibitory: GABA (gamma-aminobutyric acid), Glycine

B. Glutamate [3]

• Principal excitatory NT in the CNS (~60% of all synapses)
• Synthesis: Glutamine → (glutaminase) → Glutamate
• Receptors: NMDA, AMPA, Kainate (ionotropic); mGluR (metabotropic)
• Removal: Reuptake via EAATs → astrocytes → converted to glutamine (glutamine synthetase)

Clinical relevance:

• NMDA hypofunction model of schizophrenia (PCP psychosis)
• Excitotoxicity → stroke, neurodegeneration (ALS, Huntington's, Alzheimer's)
• Ketamine/esketamine, rapid-acting antidepressants
• Memantine, Alzheimer's treatment
• Riluzole (glutamate release inhibitor), ALS
• Epilepsy, glutamate excess drives seizures
• Lamotrigine, mood stabilizer, reduces glutamate release

C. GABA (Gamma-Aminobutyric Acid) [3]

• Principal inhibitory NT in the CNS (~40% of all synapses)
• Synthesis: Glutamate → (glutamic acid decarboxylase, GAD, requires vitamin B6/pyridoxine as cofactor) → GABA
• Degradation: GABA-transaminase → succinic semialdehyde → succinic acid (enters Krebs cycle)

Receptors:

Clinical relevance:

• Anxiety disorders: GABAergic deficit model; benzodiazepines enhance GABA-A
• Epilepsy: Reduced GABAergic inhibition → seizures. Vigabatrin (irreversible GABA-transaminase inhibitor), valproate (↑ GABA), tiagabine (GABA reuptake inhibitor)
• Insomnia: Benzodiazepines, Z-drugs (zolpidem, zopiclone) act at GABA-A
• Alcohol: Alcohol potentiates GABA-A → cross-tolerance with benzodiazepines. Withdrawal = reduced GABAergic tone → seizures, DT
• Hepatic encephalopathy: Increased endogenous benzodiazepine-like substances
• Depression: GABAergic deficit reported; brexanolone (neurosteroid GABA-A modulator) approved for postpartum depression
• Schizophrenia: GABAergic interneuron dysfunction in PFC

D. Glycine [1.5]

• Inhibitory NT predominantly in the spinal cord and brainstem
• Acts on glycine receptors (Cl⁻ channels, strychnine-sensitive)
• Also functions as obligatory co-agonist at the NMDA receptor (glycine site/GluN1 subunit)
• Clinical relevance:
• Strychnine poisoning, glycine receptor blockade → spastic paralysis, convulsions
• Glycine site agonists (e.g., D-serine, D-cycloserine) investigated as adjuncts in schizophrenia (to enhance NMDA function)
• Hyperekplexia (startle disease), mutations in glycine receptor

E. Aspartate [0.5]

• Excitatory amino acid, co-localized with glutamate
• Acts on NMDA receptors
• Less well-characterized clinical role compared to glutamate

F. Summary Table [1]

(See Q1 for detailed glutamate, Q9 for glutamate/GABA in depression)

Q4: "Relationship between neurotransmitters and various brain functions. Novel neurotransmitters.": 10 marks

A. Neurotransmitters and Brain Functions [5]

B. Novel Neurotransmitters [5]

1. Endocannabinoids

• Anandamide (AEA) and 2-arachidonoylglycerol (2-AG)
• Act on CB1 (CNS, hippocampus, basal ganglia, cerebellum) and CB2 (immune cells, periphery) receptors
• Unique: retrograde signaling, synthesized in postsynaptic neuron, travel backward to modulate presynaptic release
• Functions: pain modulation, appetite (CB1 agonism → "munchies"), mood, memory extinction (relevant to PTSD), neuroprotection
• Clinical: Cannabis (THC = CB1 partial agonist); rimonabant (CB1 antagonist, withdrawn, psychiatric side effects); CBD (complex pharmacology, anxiolytic, antipsychotic properties under investigation); nabilone/dronabinol for chemotherapy-induced nausea

2. Nitric Oxide (NO)

• Gaseous neurotransmitter, synthesized by nitric oxide synthase (NOS) from L-arginine
• Not stored in vesicles, produced on demand, diffuses freely across membranes
• Acts via soluble guanylyl cyclase → cGMP (not a classical receptor)
• Functions: cerebral vasodilation, synaptic plasticity (involved in LTP alongside glutamate/NMDA), penile erection
• Clinical: Sildenafil (PDE5 inhibitor) enhances NO/cGMP pathway; NOS inhibitors investigated in psychiatric disorders; NO involved in neuroinflammation

3. Neuropeptides (selected)

4. Purines

• Adenosine: Inhibitory NT; accumulates during wakefulness → promotes sleep. Caffeine = adenosine A1/A2A antagonist
• ATP: Co-released with other NTs; acts on P2X (ionotropic) and P2Y (metabotropic) receptors; role in pain and neuroinflammation

5. D-serine

• Co-agonist at NMDA receptor glycine site
• Released by astrocytes
• Deficiency may contribute to NMDA hypofunction in schizophrenia

(See Q1 for glutamate detail, Q3 for amino acid NTs)

Q5: "Define neurotransmitters. Describe various types of neurotransmitters. Describe role of dopamine in Psychiatry.": 10 marks

A. Definition [2]

A neurotransmitter is a chemical messenger synthesized in a neuron, stored in synaptic vesicles, released in a calcium-dependent manner upon depolarization, acts on specific postsynaptic receptors to produce a biological effect, and has a defined mechanism of inactivation.

Criteria (expanded): See Q1 Section A for the 6 classical criteria.

B. Classification of Neurotransmitters [3]

By chemical structure:

By function:

• Excitatory: Glutamate, aspartate, ACh (nicotinic), NE (some receptors)
• Inhibitory: GABA, glycine
• Modulatory: Dopamine, serotonin, NE, neuropeptides

By receptor type engaged:

• Ionotropic (fast): Glutamate (NMDA/AMPA/Kainate), GABA-A, glycine, nicotinic ACh
• Metabotropic (slow): mGluR, GABA-B, muscarinic ACh, all monoamine receptors, neuropeptide receptors

C. Role of Dopamine in Psychiatry [5]

Synthesis: Tyrosine → L-DOPA (tyrosine hydroxylase, rate-limiting) → Dopamine (DOPA decarboxylase)

Degradation: MAO-B + COMT → HVA

Receptors: D1-like (D1, D5, Gs, ↑cAMP) and D2-like (D2, D3, D4, Gi, ↓cAMP)

4 Major Pathways + Clinical Relevance:

Disorder-specific roles:

• Schizophrenia: Revised dopamine hypothesis, mesolimbic excess + mesocortical deficit + glutamate-dopamine interaction. All antipsychotics block D2. Partial agonists (aripiprazole, cariprazine, brexpiprazole) stabilize dopamine.
• Depression: Dopamine deficit in reward circuits → anhedonia, avolition. Bupropion (NDRI). Pramipexole (D3 agonist) augments antidepressants.
• Mania: Dopamine excess. Antipsychotics (D2 blockade) are mainstay of acute mania treatment.
• ADHD: Mesocortical DA/NE deficit in PFC → inattention, impulsivity. Stimulants (methylphenidate, amphetamines) increase DA/NE.
• Addiction: All substances of abuse increase mesolimbic DA. Dopamine depleted in chronic use → anhedonia, craving.
• Psychosis in Parkinson's: L-DOPA increases DA globally → mesolimbic excess → hallucinations. Pimavanserin (5-HT2A inverse agonist) preferred.
• Tourette's: Dopaminergic hyperactivity in basal ganglia. Treated with D2 blockers (haloperidol, aripiprazole).

Diagram description: Draw the 4 dopaminergic pathways as in Q2.

(Cross-references: Q1 for definitions, Q6/Q11 for expanded pathway detail)

Q6: "Describe dopaminergic pathways in the brain. What are their functions? What is their applied importance?": 10 marks

A. Introduction [1]

Dopaminergic neurons constitute a relatively small population (~400,000–600,000 in the human brain) but have disproportionately large influence on motor control, reward, motivation, cognition, and endocrine regulation. They are organized into distinct pathways originating from midbrain and hypothalamic nuclei.

B. The 5 Dopaminergic Pathways [6]

1. Mesolimbic Pathway

• Origin: Ventral tegmental area (VTA, A10 cell group)
• Termination: Nucleus accumbens (ventral striatum), amygdala, hippocampus, olfactory tubercle
• Function: Reward processing, motivation, pleasure, emotional salience, reinforcement learning
• Applied importance:
• Schizophrenia: Hyperactivity → positive symptoms (delusions, hallucinations, thought disorder). The "psychosis pathway."
• Addiction: All drugs of abuse (opioids, stimulants, alcohol, nicotine) converge on this pathway → DA surge in NAc
• Depression: Hypoactivity → anhedonia, reduced motivation
• Antipsychotic D2 blockade here → reduces positive symptoms

2. Mesocortical Pathway

• Origin: VTA (A10)
• Termination: Prefrontal cortex, dorsolateral PFC (DLPFC) and ventromedial PFC (VMPFC)
• Function:
• DLPFC: Working memory, executive function, planning
• VMPFC: Emotion regulation, social cognition, decision-making
• Applied importance:
• Schizophrenia: Hypoactivity → negative symptoms (avolition, alogia, flat affect) and cognitive symptoms (poor working memory, impaired executive function)
• ADHD: DA/NE deficit in PFC → inattention, poor executive function
• Antipsychotic D2 blockade here → can WORSEN negative/cognitive symptoms (clinical dilemma)
• Second-generation antipsychotics (5-HT2A antagonism) may improve mesocortical DA tone

3. Nigrostriatal Pathway

• Origin: Substantia nigra pars compacta (SNpc, A9 cell group)
• Termination: Dorsal striatum (caudate nucleus and putamen)
• Function: Initiation and modulation of voluntary movement, procedural learning, habit formation
• Applied importance:
• Parkinson's disease: Degeneration of SNpc neurons → 70–80% DA loss → bradykinesia, rigidity, tremor
• Antipsychotic-induced EPS: D2 blockade in this pathway → acute dystonia, parkinsonism, akathisia, tardive dyskinesia
• Tardive dyskinesia: Chronic D2 blockade → receptor upregulation/supersensitivity → involuntary choreoathetoid movements. Treatment: valbenazine, deutetrabenazine (VMAT2 inhibitors)
• Tourette syndrome: DA hyperactivity in basal ganglia
• Huntington's disease: Loss of GABAergic medium spiny neurons in striatum → disinhibition of DA → chorea

4. Tuberoinfundibular Pathway

• Origin: Arcuate nucleus and periventricular nucleus of hypothalamus (A12)
• Termination: Median eminence → pituitary stalk → anterior pituitary
• Function: Tonic dopamine release inhibits prolactin secretion from lactotroph cells
• Applied importance:
• Antipsychotic-induced hyperprolactinemia: D2 blockade removes tonic inhibition → ↑ prolactin → galactorrhea, amenorrhea, sexual dysfunction, osteoporosis (long-term)
• Risperidone and amisulpride, highest risk. Aripiprazole (partial D2 agonist), lowest risk, can even reverse hyperprolactinemia
• Prolactinoma: DA agonists (cabergoline, bromocriptine) shrink tumor

5. Thalamic Pathway (newer)

• Origin: Multiple sources including periaqueductal gray, VTA, hypothalamus
• Termination: Thalamus
• Function: Arousal, wakefulness, sensory gating
• Applied importance: May contribute to mechanism of sleep disturbance, altered consciousness; less well-characterized clinically

C. Integrated Clinical Application [2]

The antipsychotic dilemma:

• Effective antipsychotic action requires D2 blockade in mesolimbic pathway
• But D2 blockade simultaneously causes:
• Mesocortical: worsened negative/cognitive symptoms
• Nigrostriatal: EPS
• Tuberoinfundibular: hyperprolactinemia
• Solution approaches:
• Partial D2 agonists (aripiprazole, cariprazine, brexpiprazole), stabilize DA across all pathways
• 5-HT2A antagonism (clozapine, quetiapine, olanzapine), increases DA release in nigrostriatal and mesocortical pathways, reducing EPS and negative symptoms
• Low D2 affinity/fast dissociation (quetiapine, clozapine), "hit and run" pharmacology

Diagram description: Draw a sagittal brain section showing: VTA (mesolimbic → NAc; mesocortical → PFC), SN (nigrostriatal → striatum), hypothalamus (tuberoinfundibular → pituitary). Color-code each pathway. Label clinical consequences of blockade at each endpoint.

D. Summary Table [1]

Q7: "Discuss serotonin-related pathways and its relevance to psychiatric disorders.": 10 marks

A. Serotonin (5-Hydroxytryptamine, 5-HT): Basics [2]

Synthesis: Tryptophan → (tryptophan hydroxylase, TPH, rate-limiting) → 5-hydroxytryptophan (5-HTP) → (aromatic L-amino acid decarboxylase) → Serotonin (5-HT)

Degradation: MAO-A → 5-HIAA (5-hydroxyindoleacetic acid; measurable in CSF, low in suicidal patients)

Storage: SERT (serotonin transporter) mediates reuptake. Stored in vesicles by VMAT2.

Location: Only ~2% of body's serotonin is in the CNS. 95% is in the gut (enterochromaffin cells). Remainder in platelets.

B. Serotonergic Pathways [3]

Origin: Raphe nuclei (midline brainstem), especially:

• Dorsal raphe nucleus (DRN), largest; projects widely to cortex, limbic, basal ganglia
• Median raphe nucleus (MRN), projects to hippocampus, septum

Projections (ascending):

C. Serotonin Receptor Subtypes (14 subtypes in 7 families) [2]

D. Relevance to Psychiatric Disorders [3]

1. Depression

• Monoamine hypothesis: 5-HT deficit → depression. Evidence: reserpine (depletes 5-HT) → depression; tryptophan depletion → relapse in remitted patients
• SSRIs (fluoxetine, sertraline, etc.), block SERT → ↑ synaptic 5-HT
• SNRIs, TCAs, MAOIs also increase 5-HT
• Low CSF 5-HIAA correlates with suicidality (especially violent/impulsive attempts)

2. Anxiety Disorders

• 5-HT modulates amygdala reactivity
• SSRIs are first-line for GAD, panic disorder, social anxiety, OCD, PTSD
• Buspirone (5-HT1A partial agonist), GAD

3. OCD

• Serotonin hypothesis: clomipramine (potent SRI) > desipramine (NRI) in OCD
• Higher SSRI doses needed for OCD vs. depression
• 5-HT dysregulation in cortico-striato-thalamo-cortical (CSTC) circuit

4. Schizophrenia

• 5-HT2A antagonism is the hallmark of atypical antipsychotics
• Psychedelics (5-HT2A agonists) produce perceptual disturbances resembling psychosis
• Pimavanserin, pure 5-HT2A inverse agonist for Parkinson's psychosis

5. Eating Disorders

• 5-HT regulates satiety (5-HT2C in hypothalamus)
• Bulimia: fluoxetine (60 mg) is FDA-approved
• Anorexia: serotonergic dysregulation persists after weight restoration

6. Aggression and Impulsivity

• Low serotonergic tone → impulsive aggression (low 5-HIAA in CSF)
• SSRIs reduce impulsive aggression in personality disorders

7. Sleep

• 5-HT from DRN promotes wakefulness; involved in sleep-wake regulation
• SSRIs suppress REM sleep, increase REM latency

8. Pain

• Descending serotonergic pathways from raphe → dorsal horn modulate pain
• SNRIs (duloxetine) and TCAs (amitriptyline), analgesic via 5-HT + NE

(See Q8 for neurochemistry focus, Q14/Q15 for serotonin syndrome)

Q8: "Describe neurochemistry of serotonin. Discuss the role of serotonin in psychiatric disorders.": 10 marks

A. Neurochemistry of Serotonin [5]

Synthesis:

1. Tryptophan (essential amino acid from diet) → crosses BBB via large neutral amino acid transporter (competes with other amino acids, explains high-carb meals increasing brain tryptophan)
2. Tryptophan → 5-Hydroxytryptophan (5-HTP) by enzyme tryptophan hydroxylase (TPH), rate-limiting step
3. TPH1: peripheral (gut), TPH2: CNS-specific
4. Requires molecular oxygen, iron, and tetrahydrobiopterin (BH4) as cofactors
5. 5-HTP → Serotonin (5-HT) by aromatic L-amino acid decarboxylase (AADC), requires pyridoxal phosphate (vitamin B6)

Storage and Release:

• Packaged into vesicles by VMAT2 (vesicular monoamine transporter 2)
• Released by Ca²⁺-dependent exocytosis
• Acts on 14 receptor subtypes (7 families: 5-HT1–5-HT7)

Reuptake:

• SERT (serotonin transporter / SLC6A4): Primary mechanism of inactivation
• SERT is the target of SSRIs, SNRIs, TCAs, MDMA (ecstasy, reverses SERT to cause 5-HT release)
• 5-HTTLPR polymorphism: Short allele associated with reduced SERT expression → increased amygdala reactivity → vulnerability to depression under stress (Caspi et al., 2003, though meta-analyses show complex picture)

Degradation:

• MAO-A (monoamine oxidase A) in mitochondria → 5-HIAA (5-hydroxyindoleacetic acid)
• 5-HIAA excreted in urine (elevated in carcinoid syndrome)
• Low CSF 5-HIAA: biomarker for impulsive aggression and suicidality

Autoreceptor Regulation:

• 5-HT1A autoreceptors (somatodendritic, on raphe neurons): Detect rising 5-HT → negative feedback → reduce firing
• 5-HT1B/1D autoreceptors (presynaptic terminal): Reduce 5-HT release
• SSRI therapeutic lag (2–4 weeks): Initially, increased 5-HT activates autoreceptors → reduced firing. Over weeks, autoreceptors desensitize → increased serotonergic transmission.

Key pharmacological interactions:

B. Role in Psychiatric Disorders [5]

(See Q7 Section D for expanded detail; key points summarized here)

Q9: "Role of glutamate and GABA neurotransmitters in depression.": 10 marks

A. Introduction [1]

The monoamine hypothesis of depression (serotonin/norepinephrine deficit) has been the dominant model but explains only part of the picture. Evidence now strongly supports roles for glutamate (excitatory) and GABA (inhibitory) neurotransmitter systems in the pathophysiology and treatment of depression.

B. Glutamate in Depression [4]

Evidence for glutamatergic dysfunction:

• ↑ Glutamate levels in plasma, CSF, and brain (MRS studies) of depressed patients
• ↑ Glutamate in PFC and limbic regions correlates with severity
• Chronic stress → ↑ glucocorticoids → ↑ glutamate release → excitotoxicity → dendritic atrophy and synaptic loss, especially in PFC and hippocampus
• Reduced glial cells (astrocytes) in PFC of depressed patients → impaired glutamate clearance → further excitotoxicity
• NMDA receptor: altered subunit expression in postmortem brains of depressed/suicidal patients

NMDA receptor hypofunction model:

• Ketamine (NMDA antagonist) produces rapid (within hours) antidepressant effects
• Mechanism: NMDA blockade on GABAergic interneurons → disinhibition of glutamate release → AMPA receptor activation → BDNF release → mTOR signaling → rapid synaptogenesis and restoration of synaptic connections in PFC
• This is the "synaptogenic hypothesis" of rapid antidepressant action

Therapeutic implications, glutamate-targeting drugs:

mGluR targets:

• mGluR5 negative allosteric modulators (NAMs), antidepressant and anxiolytic properties in preclinical studies
• mGluR2/3 antagonists, enhance glutamate release → antidepressant-like effects

C. GABA in Depression [4]

Evidence for GABAergic deficit:

• ↓ GABA levels in plasma, CSF, and occipital cortex (MRS) of depressed patients
• ↓ GAD67 (GABA synthesizing enzyme) in PFC of depressed patients (postmortem)
• ↓ GABA-A receptor binding in parahippocampal and temporal cortex
• Reduced GABAergic interneuron density in PFC (specific subtypes: somatostatin-positive and parvalbumin-positive interneurons)
• Normalize after successful antidepressant treatment (GABA levels rise with SSRIs, ECT)

Neurosteroids and GABA in depression:

• Allopregnanolone is an endogenous neurosteroid that is a potent positive allosteric modulator of GABA-A receptors
• ↓ Allopregnanolone levels found in depression, especially peripartum depression
• Stress → ↓ allopregnanolone → ↓ GABAergic inhibition → ↑ HPA axis activation → depressive symptoms

Therapeutic implications, GABA-targeting drugs:

Benzodiazepines: Not antidepressants per se, but short-term adjuncts for anxiety/insomnia in depression. GABA-A agonism does not reverse the core depressive syndrome.

D. Integration: Glutamate-GABA Imbalance Model [1]

• Depression involves a disrupted excitatory-inhibitory (E/I) balance in key circuits (PFC, hippocampus, amygdala)
• Chronic stress → glucocorticoid excess → ↑ glutamate + ↓ GABA → excitotoxicity + loss of inhibitory control
• This leads to: dendritic atrophy (PFC), synaptic loss, reduced neuroplasticity, amygdala hyperactivity
• Ketamine and neurosteroids may work by rapidly restoring E/I balance and triggering synaptogenesis
• The field is moving from "monoamine restoration" (weeks) to "synaptic repair" (hours-days) as the paradigm for antidepressant action

Diagram description: Draw a balance scale, left side = glutamate (excitatory), right side = GABA (inhibitory). In health: balanced. In depression: glutamate side tips down (excess) and GABA side rises (deficit). Show arrows: chronic stress → glucocorticoids → glutamate excess + GABA deficit → excitotoxicity + HPA overactivation → depression. Treatment: ketamine (blocks excess glutamate signaling), neurosteroids (enhance GABA).

Q10: "Define neurotransmitters. Mono-amine neurotransmitters and its significance in psychiatric disorders.": 10 marks

A. Definition [2]

(See Q1 Section A, use same 6-point definition)

A neurotransmitter is a chemical substance synthesized in a neuron, stored in vesicles, released in Ca²⁺-dependent manner upon depolarization, acts on specific postsynaptic receptors, and has a defined inactivation mechanism. Can be mimicked by exogenous application and blocked by specific antagonists.

B. Monoamine Neurotransmitters: Classification [2]

Monoamines contain one amino group connected to an aromatic ring by a two-carbon chain. They are subdivided into:

Shared features:

• Synthesized by specific enzymes with rate-limiting steps
• Stored in vesicles by VMAT2
• Removed from synapse by reuptake transporters (DAT, NET, SERT) and degraded by MAO and COMT
• All act primarily on metabotropic (G-protein coupled) receptors

C. Significance in Psychiatric Disorders [6]

1. Dopamine

(See Q2, Q5, Q6 for detailed pathways)

• Schizophrenia: Mesolimbic hyperactivity → positive symptoms; mesocortical hypoactivity → negative symptoms
• Depression: Mesocortical/mesolimbic deficit → anhedonia
• Mania: DA excess contributes to elevated mood, grandiosity
• ADHD: PFC DA/NE deficit → inattention
• Addiction: Mesolimbic DA surge → reinforcement
• Parkinson's disease: Nigrostriatal DA loss
• Drugs acting on DA: Antipsychotics (D2 blockers), stimulants (DA/NE releasers), bupropion (NDRI), L-DOPA

2. Serotonin (5-HT)

(See Q7, Q8 for detailed pathways)

• Depression: 5-HT deficit; ↓ CSF 5-HIAA correlates with suicidality
• Anxiety disorders: Amygdala hyperreactivity; SSRIs first-line
• OCD: 5-HT dysfunction in CSTC circuit; high-dose SSRIs
• Eating disorders: 5-HT modulates satiety
• Impulsive aggression: Low 5-HT → disinhibition
• Drugs: SSRIs, SNRIs, TCAs, MAOIs, buspirone, trazodone, vortioxetine

3. Norepinephrine (NE)

• Origin: Locus coeruleus (LC) → widespread cortical, limbic, spinal projections
• Functions: Arousal, attention, vigilance, fight-or-flight, mood, pain modulation
• Receptors: Alpha-1 (postsynaptic, excitatory), Alpha-2 (presynaptic autoreceptor, inhibitory), Beta-1/2/3
• Depression: NE deficit model; SNRIs (duloxetine, venlafaxine), NRIs (reboxetine), TCAs increase NE
• Anxiety/PTSD: NE hyperactivity → hyperarousal, hypervigilance. Prazosin (alpha-1 antagonist) → reduces PTSD nightmares. Clonidine, guanfacine (alpha-2 agonists) → reduce NE release
• ADHD: NE deficit in PFC. Atomoxetine (selective NRI), guanfacine, clonidine
• Panic disorder: LC hyperactivity → panic attacks. Yohimbine (alpha-2 antagonist) triggers panic in vulnerable individuals

4. Histamine

• Origin: Tuberomammillary nucleus (TMN) of posterior hypothalamus → widespread
• Receptors: H1 (Gq, wakefulness, allergy), H2 (Gs, gastric acid), H3 (Gi, presynaptic autoreceptor, regulates HA/other NT release), H4 (immune)
• Functions: Wakefulness, appetite, cognition, immune modulation
• Clinical:
• H1 blockade → sedation, weight gain (major side effect of olanzapine, quetiapine, mirtazapine, TCAs, first-generation antihistamine sedatives)
• H3 antagonists/inverse agonists (pitolisant) → promote wakefulness → narcolepsy treatment
• Antihistamines (diphenhydramine, hydroxyzine) → used as anxiolytics/sedatives in psychiatry

5. Epinephrine

• Relatively minor role in CNS compared to NE
• Synthesized from NE by phenylethanolamine N-methyltransferase (PNMT)
• Primarily adrenal medulla (peripheral stress response)
• CNS: small number of epinephrine neurons in brainstem → involved in autonomic regulation, blood pressure

D. The Monoamine Hypothesis of Depression [Additional scoring point]

• Original: Depression = deficit of monoamines (5-HT, NE, DA)
• Evidence for: Reserpine (depletes monoamines) → depression; all effective antidepressants increase monoamines
• Evidence against: Antidepressants increase monoamines within hours but therapeutic effect takes weeks; tryptophan depletion causes relapse only in previously depressed (not healthy); no consistent monoamine deficit found in unmedicated depression
• Revised model: Monoamine deficit → downstream effects on neuroplasticity (BDNF), HPA axis, neuroinflammation, and glutamate/GABA balance. Antidepressants work by restoring these downstream processes.

Q11: "Major dopaminergic pathways of human brain. Implications and relevance of dopamine in Psychiatry.": 10 marks

(This answer overlaps extensively with Q6. Write the same pathway table and clinical relevance. Key additions/emphasis:)

Answer: Follow Q6 structure exactly.

A. Major Dopaminergic Pathways [5]

B. Implications and Relevance [5]

Summary table, Dopamine in Psychiatric Disorders:

(See Q2, Q5, Q6 for expanded discussions of each pathway)

Q12: "What are the characteristics of a neurotransmitter? Enumerate some inhibitory neurotransmitters.": 10 marks

A. Characteristics (Criteria) of a Neurotransmitter [5]

A chemical substance must satisfy the following criteria to be classified as a neurotransmitter:

1. Synthesis: Must be synthesized within the presynaptic neuron. The necessary precursors and enzymes must be present in the neuron.

1. Storage: Must be stored in synaptic vesicles at the presynaptic terminal (packaged by vesicular transporters, e.g., VMAT2 for monoamines, VGLUT for glutamate, VGAT for GABA).

1. Release: Must be released into the synaptic cleft upon depolarization of the presynaptic terminal in a calcium-dependent manner (Ca²⁺ influx through voltage-gated Ca²⁺ channels → vesicle fusion → exocytosis).

1. Receptor action: Must bind to specific receptors on the postsynaptic membrane (or presynaptic, autoreceptors) and produce a measurable biological effect (EPSP or IPSP).

1. Inactivation: Must have a mechanism for termination of action, one or more of:
2. Reuptake by specific transporters (SERT, DAT, NET, EAAT)
3. Enzymatic degradation (MAO, COMT, AChE, GABA-T)
4. Diffusion away from the synapse

1. Mimicry and Antagonism: Exogenous application should mimic the effect of nerve stimulation. Specific antagonists should block the response.

1. Identity of action: The substance released by nerve stimulation must be identical to the substance that produces the postsynaptic response when applied experimentally.

Additional modern criteria:

• Can be detected immunohistochemically in the neuron
• Knockout/knockdown of synthesis enzyme should abolish the function

B. Inhibitory Neurotransmitters [5]

1. GABA (Gamma-Aminobutyric Acid), the principal inhibitory NT in the CNS

• Synthesis: Glutamate → (GAD + vitamin B6) → GABA
• Receptors: GABA-A (ionotropic, Cl⁻), GABA-B (metabotropic)
• Produces IPSPs by increasing Cl⁻ conductance (hyperpolarization)
• ~40% of CNS synapses are GABAergic
• Clinical: Anxiety (benzodiazepines enhance GABA-A), epilepsy (valproate, vigabatrin ↑ GABA), insomnia (Z-drugs at GABA-A), alcohol action

2. Glycine, principal inhibitory NT in spinal cord and brainstem

• Receptor: Strychnine-sensitive glycine receptor (Cl⁻ channel)
• Important for spinal motor reflex inhibition
• Also co-agonist at NMDA receptor (excitatory, dual role)
• Clinical: Strychnine poisoning (glycine blockade → convulsions), hyperekplexia

3. Serotonin (5-HT), inhibitory in some circuits

• 5-HT1A activation in raphe nuclei → autoinhibition
• 5-HT modulates and often inhibits downstream neurons (e.g., reduces amygdala output)
• Not a pure inhibitory NT, can be excitatory at 5-HT2/5-HT3 receptors

4. Dopamine, inhibitory in some circuits

• D2 receptor activation → Gi → ↓cAMP → inhibitory
• Tuberoinfundibular: DA inhibits prolactin release
• Not purely inhibitory

5. Norepinephrine, inhibitory via alpha-2 receptors

• Alpha-2 autoreceptors → presynaptic inhibition
• Postsynaptic alpha-2 → inhibitory in some brain regions

6. Adenosine, inhibitory neuromodulator

• A1 receptor → Gi → inhibits neurotransmitter release, reduces neuronal excitability
• Accumulates during wakefulness → promotes sleep
• Caffeine = adenosine antagonist

7. Endocannabinoids (anandamide, 2-AG), inhibitory via retrograde signaling

• CB1 receptor → Gi → reduce presynaptic NT release (both glutamate and GABA)
• Net effect often inhibitory on excitatory transmission

8. Opioid peptides (endorphins, enkephalins, dynorphins), inhibitory

• Mu, kappa, delta receptors → Gi → ↓cAMP, ↑K⁺ conductance, ↓Ca²⁺
• Pain inhibition, reward modulation

Q13: "Define receptors. Discuss various neurotransmitters relevant to affective disorders.": 10 marks

A. Definition and Classification of Receptors [3]

A receptor is a protein molecule (usually on the cell surface or intracellular) that specifically recognizes and binds a ligand (neurotransmitter, hormone, drug) and transduces this binding event into a cellular response.

Properties of receptors:

• Specificity: Binds only structurally complementary ligands
• Saturability: Finite number of receptors (can be measured, Bmax)
• Affinity: Measured by Kd (dissociation constant)
• Reversibility: Ligand binding is typically reversible
• Signal transduction: Binding leads to a biological effect

Classification of Neurotransmitter Receptors:

G-protein families:

B. Neurotransmitters Relevant to Affective Disorders [7]

Affective disorders = Major Depressive Disorder (MDD) and Bipolar Disorder (BD).

1. Serotonin (5-HT), the most studied

• ↓ 5-HT → depression; ↓ 5-HIAA in CSF → suicidality
• Tryptophan depletion → relapse in remitted depressed patients
• 5-HT1A receptor downregulation in depression
• SSRIs, SNRIs, MAOIs, all increase 5-HT availability
• In bipolar: SSRIs can trigger mania (switch), reflects serotonin-dopamine interaction

2. Norepinephrine (NE)

• ↓ NE → depression (psychomotor retardation, fatigue, poor concentration)
• ↑ NE → mania, mixed states
• Evidence: MHPG (NE metabolite) ↓ in depressed, ↑ in manic patients (some studies)
• Alpha-2 autoreceptor supersensitivity proposed in depression
• Drugs: SNRIs, TCAs (NRI component), mirtazapine (alpha-2 antagonist → ↑ NE)

3. Dopamine (DA)

• ↓ DA (mesocortical/mesolimbic) → anhedonia, psychomotor retardation, lack of motivation, core depression features
• ↑ DA → mania (elevated mood, increased goal-directed activity, grandiosity)
• Evidence: bupropion (NDRI) effective in depression; pramipexole (D3 agonist) augments antidepressants; all antimanic agents reduce DA (antipsychotics, lithium)
• HVA levels: ↓ in depression, ↑ in mania

4. Glutamate

• ↑ Glutamate in PFC/limbic regions in depression (MRS studies)
• Excitotoxicity → synaptic loss → depression
• Ketamine/esketamine, NMDA antagonist → rapid antidepressant action
• Dextromethorphan/bupropion (Auvelity), approved for MDD
• Lamotrigine (↓ glutamate release), effective in bipolar depression

5. GABA

• ↓ GABA in cortex/plasma of depressed patients
• ↓ GABAergic interneuron function in PFC
• Brexanolone (GABA-A PAM), approved for postpartum depression
• Zuranolone (oral GABA-A PAM), approved for postpartum depression
• Valproate (↑ GABA), mood stabilizer in bipolar

6. Acetylcholine (ACh)

• Cholinergic-adrenergic balance hypothesis (Janowsky): ↑ ACh / ↓ NE = depression; ↓ ACh / ↑ NE = mania
• Evidence: Physostigmine (AChE inhibitor) → depressive symptoms; scopolamine (muscarinic antagonist) → rapid antidepressant effect (under investigation)
• Nicotinic receptor involvement in mood regulation

7. Neuropeptides and Hormones

• CRH: ↑ in depression → HPA axis hyperactivation → hypercortisolism
• Substance P: NK1 receptor antagonists showed initial antidepressant promise (not replicated)
• Thyroid hormones: T3 augmentation in treatment-resistant depression; hypothyroidism → depression; hyperthyroidism → mania-like symptoms
• BDNF: Neurotrophin, not a classical NT but downstream effector, ↓ in depression, ↑ with antidepressant treatment (neuroplasticity hypothesis)

Q14: "Define serotonin syndrome and discuss its treatment.": 10 marks

A. Definition [2]

Serotonin syndrome is a potentially life-threatening adverse drug reaction resulting from excess serotonergic activity in the central and peripheral nervous systems. It is caused by therapeutic drug use, intentional overdose, or drug interactions involving serotonergic agents.

It is a clinical diagnosis, no confirmatory laboratory test exists.

It occurs due to excessive stimulation of 5-HT1A and 5-HT2A receptors (centrally and peripherally).

B. Etiology: Common Causative Combinations [1]

C. Clinical Features [3]

Triad: (1) Neuromuscular excitability, (2) Autonomic dysfunction, (3) Altered mental status

Hunter Serotonin Toxicity Criteria (most widely accepted diagnostic criteria):

In the presence of a serotonergic agent, serotonin syndrome is diagnosed if ANY ONE of:

1. Spontaneous clonus
2. Inducible clonus + (agitation OR diaphoresis)
3. Ocular clonus + (agitation OR diaphoresis)
4. Tremor + hyperreflexia
5. Hypertonia + temperature >38°C + (ocular clonus OR inducible clonus)

Severity spectrum:

• Mild: Tremor, hyperreflexia, tachycardia, diaphoresis, mydriasis, diarrhea
• Moderate: Clonus (ocular/inducible), agitation, hyperthermia, hyperreflexia
• Severe: Spontaneous clonus, severe hyperthermia (>41.1°C), rigidity, autonomic instability, delirium, seizures, rhabdomyolysis, DIC, metabolic acidosis, multi-organ failure, death

D. Differential Diagnosis [1]

E. Treatment [3]

1. Discontinue ALL serotonergic agents, MOST IMPORTANT STEP

2. Supportive care:

• Mild: Observation, IV fluids, benzodiazepines for agitation/myoclonus, cardiac monitoring. Usually resolves within 24–72 hours.
• Moderate-Severe: ICU admission

3. Specific pharmacotherapy:

4. Hyperthermia management:

• Active cooling (cooling blankets, ice packs, evaporative cooling)
• Benzodiazepines for muscle rigidity (reduces heat generation)
• Severe (>41.1°C): Consider intubation + neuromuscular paralysis (non-depolarizing agents, succinylcholine CONTRAINDICATED due to rhabdomyolysis/hyperkalemia risk) + mechanical ventilation
• Antipyretics (paracetamol) are INEFFECTIVE, hyperthermia is due to muscular hyperactivity, not hypothalamic set-point change

5. Avoid:

• Dantrolene (no evidence of benefit in SS, unlike NMS)
• Bromocriptine (used in NMS, not SS)
• Physical restraints (increase risk of rhabdomyolysis and lactic acidosis)

6. Monitoring:

• Core temperature, vital signs, mental status
• CK, renal function, electrolytes, coagulation (DIC screening in severe cases)

Prognosis: Most cases resolve within 24–72 hours after stopping the offending agent (depending on drug half-life). Mortality rare with prompt treatment. Deaths typically from severe hyperthermia and multiorgan failure.

(See Q15 for expanded management + prevention focus)

Q15: "Discuss clinical presentation and management of serotonin syndrome. Also focus on preventive steps.": 10 marks

A. Clinical Presentation [3]

(Same as Q14 Section C, use Hunter criteria)

Onset: Typically within 6–24 hours of drug initiation, dose increase, or addition of a second serotonergic agent. 60% of cases present within 6 hours.

Hunter Criteria: Requires presence of a serotonergic agent + any one of:

1. Spontaneous clonus
2. Inducible clonus + agitation OR diaphoresis
3. Ocular clonus + agitation OR diaphoresis
4. Tremor + hyperreflexia
5. Hypertonia + temperature >38°C + ocular/inducible clonus

Examination findings:

• Lower limb > upper limb clonus
• Hyperreflexia (patellar, ankle)
• Ocular clonus (slow, continuous, lateral eye movements)
• Diaphoresis (wet skin, distinguishes from anticholinergic toxicity where skin is dry)
• Bowel sounds increased (vs. absent in anticholinergic toxicity)

B. Management [4]

(Same principles as Q14 Section E, formatted for quick recall)

Step 1: STOP all serotonergic agents [most critical]

Step 2: Severity-based approach:

Key drugs:

• Cyproheptadine, first-line specific antidote (5-HT2A antagonist). 12 mg stat PO/NG, then 2 mg q2h. Maintenance: 8 mg q6h.
• Benzodiazepines, agitation, myoclonus, seizures, reduces muscular hyperactivity
• Avoid: Antipyretics (ineffective), succinylcholine (hyperkalemia risk), physical restraints (↑ rhabdomyolysis)

C. Preventive Steps [3]

1. Drug awareness and avoidance of dangerous combinations:

2. Safe switching protocols:

• SSRI to MAOI: Washout of ≥2 weeks (5× half-life). Fluoxetine → MAOI: 5 weeks (norfluoxetine t½ = 4–16 days)
• MAOI to SSRI: Washout of ≥2 weeks
• When adding serotonergic agents, start low and titrate slowly

3. Patient and prescriber education:

• Educate patients about symptoms of serotonin syndrome, seek emergency care if tremor, rigidity, confusion, fever occur after starting/changing medication
• Warn about OTC serotonergic agents: dextromethorphan (in cough syrups), St. John's Wort, tryptophan supplements
• Drug interaction checking before prescribing (electronic alerts in EMR)
• Coordinate with other prescribers (e.g., neurologist prescribing triptans while psychiatrist prescribes SSRI)

4. Special populations requiring vigilance:

• Elderly (polypharmacy, reduced metabolism)
• Patients on multiple serotonergic agents
• Perioperative patients (fentanyl, meperidine, tramadol, methylene blue, all serotonergic)
• Patients on linezolid (antibiotic, reversible MAOI)

5. Monitoring after initiation:

• When starting serotonergic agents or making combinations, monitor for early signs (tremor, restlessness, diarrhea) within first 24 hours
• Have a low threshold for recognition, mild symptoms can escalate rapidly

SECTION B: NEUROANATOMY PYQs (Q16–Q21)

Q16: "Structure and functions of Basal Ganglion.": 10 marks

A. Components of the Basal Ganglia [2]

Associated structures: Ventral pallidum (limbic output), pedunculopontine nucleus

B. Circuitry: Direct and Indirect Pathways [4]

Input: Cortex → Striatum (glutamatergic, excitatory)

Direct Pathway (facilitates movement):

Cortex → Striatum (D1 receptors) → inhibits GPi/SNpr (GABAergic) → disinhibits thalamus → Thalamus excites cortex → Movement facilitated

Indirect Pathway (suppresses movement):

Cortex → Striatum (D2 receptors) → inhibits GPe → GPe disinhibits STN → STN excites GPi/SNpr → GPi/SNpr inhibits thalamus → Movement suppressed

Hyperdirect Pathway:

Cortex → STN (directly) → GPi → inhibits thalamus → rapid action cancellation (relevant to impulsivity/OCD)

Dopamine's modulatory role:

• D1 receptors on direct pathway neurons → facilitates (Go signal)
• D2 receptors on indirect pathway neurons → inhibits indirect pathway → net facilitation
• DA from SNpc therefore promotes movement via both pathways
• DA loss (Parkinson's) → ↓ direct + ↑ indirect → net inhibition → bradykinesia

Diagram description: Draw a flowchart: Cortex → Striatum (splits into direct and indirect). Direct: Striatum –(GABA)→ GPi/SNpr –(GABA)→ Thalamus → Cortex. Indirect: Striatum –(GABA)→ GPe –(GABA)→ STN –(Glut)→ GPi/SNpr –(GABA)→ Thalamus. Show DA from SNpc to striatum modulating both. Label D1 (direct) and D2 (indirect).

C. Functions of Basal Ganglia [2]

D. Clinical Disorders [2]

(See Q17 for overlapping content with emphasis on dysfunction)

Q17: "Name the components of the basal ganglia. Describe the functions and disorders due to dysfunction of basal ganglia.": 10 marks

A. Components [2]

(Same as Q16 Section A)

Core components:

1. Striatum, Caudate + Putamen (dorsal); Nucleus accumbens (ventral)
2. Globus pallidus, GPe (external) + GPi (internal)
3. Subthalamic nucleus (STN)
4. Substantia nigra, SNpc (dopaminergic) + SNpr (GABAergic output)

Collective terms:

• Corpus striatum = Caudate + Putamen + Globus pallidus
• Lentiform/Lenticular nucleus = Putamen + Globus pallidus
• Neostriatum = Caudate + Putamen

B. Functions [3]

1. Motor control: Initiation, scaling, and sequencing of voluntary movements via direct/indirect pathway balance
2. Procedural learning: Habit formation, skill learning (riding a bicycle)
3. Cognitive processing: Caudate-DLPFC loop → working memory, planning, cognitive flexibility
4. Emotion/Motivation: Ventral striatum → reward, motivation, emotional salience
5. Action selection: Go (direct pathway, D1) vs. No-Go (indirect pathway, D2), selecting appropriate actions while suppressing inappropriate ones
6. Impulse control: Hyperdirect pathway (cortex → STN) enables rapid action cancellation
7. Eye movements: Caudate → SNpr → superior colliculus → saccades

C. Disorders Due to Basal Ganglia Dysfunction [5]

Hypokinetic Disorders (↓ movement):

Hyperkinetic Disorders (↑ movement):

Psychiatric Disorders with Basal Ganglia Involvement:

Q18: "Frontal Lobe function tests.": 10 marks

A. Overview of Frontal Lobe Functions [2]

B. Tests of Frontal Lobe Function [8]

1. Executive Function / DLPFC Tests:

2. Behavioral / OFC Tests:

3. Motor Sequencing / Premotor Tests:

4. Bedside / Clinical Tests:

5. Comprehensive Neuropsychological Batteries:

(See Q19 for frontal lobe syndromes, the clinical correlates of these test abnormalities)

Q19: "Describe the clinical features of frontal lobe syndromes.": 10 marks

A. Introduction [1]

The frontal lobe constitutes ~1/3 of the cerebral cortex and is critical for executive function, personality, social behavior, motivation, and motor control. Frontal lobe syndromes are categorized based on the subregion involved. Historically, the case of Phineas Gage (1848), who survived a tamping iron through his OFC, first demonstrated the link between frontal damage and personality change.

B. Three Classic Frontal Lobe Syndromes [7]

1. Dorsolateral Prefrontal Syndrome (Dysexecutive Syndrome)

Lesion: DLPFC (Brodmann areas 9, 10, 46)

2. Orbitofrontal Syndrome (Disinhibition Syndrome / Pseudopsychopathic Personality)

Lesion: OFC (Brodmann areas 11, 12, 47)

Phineas Gage: Classic example, became "fitful, irreverent, impatient, profane" after OFC destruction, despite intact memory and intellect.

3. Medial Frontal / Anterior Cingulate Syndrome (Apathetic/Akinetic Syndrome / Pseudodepressive Personality)

Lesion: Medial frontal cortex, anterior cingulate cortex (ACC), supplementary motor area

C. Other Frontal Lobe Features [1]

D. Causes of Frontal Lobe Syndromes [1]

• Traumatic brain injury (most common, frontal and temporal lobes are most vulnerable to contrecoup injury)
• Cerebrovascular disease (ACA territory infarcts → medial frontal; MCA → dorsolateral)
• Tumors (meningiomas, especially olfactory groove, falx; gliomas)
• Frontotemporal dementia (FTD), behavioral variant involves OFC and medial frontal atrophy
• Neurosyphilis (GPI, general paresis of the insane)
• Multiple sclerosis (white matter lesions disconnecting frontal circuits)
• Normal pressure hydrocephalus (triad: gait apraxia, incontinence, dementia, frontal features)
• Alcoholic brain damage (frontal atrophy)

Q20: "What is Chrono-biology? How is it relevant to Psychiatry?": 10 marks

A. Definition [2]

Chronobiology is the scientific study of biological rhythms, cyclic variations in physiological and behavioral processes. It encompasses:

The master clock is the suprachiasmatic nucleus (SCN) of the anterior hypothalamus.

B. The Circadian System [3]

The SCN:

• Located above the optic chiasm in the anterior hypothalamus
• Contains ~20,000 neurons with intrinsic rhythmicity
• Receives light input via the retinohypothalamic tract (RHT) from intrinsically photosensitive retinal ganglion cells (ipRGCs) containing melanopsin (sensitive to blue light ~480 nm)
• Generates an endogenous rhythm of ~24.2 hours (slightly longer than 24h)
• Entrained (synchronized) to the environment primarily by light (the dominant zeitgeber)

Molecular clock mechanism:

• Transcription-translation feedback loop:
• CLOCK + BMAL1 proteins → activate transcription of PER and CRY genes
• PER and CRY proteins accumulate → inhibit CLOCK/BMAL1 → ↓ their own transcription
• Cycle takes ~24 hours
• Clock gene polymorphisms associated with mood disorders, chronotype, and sleep disturbances

Key circadian outputs:

• Melatonin: Synthesized by pineal gland; suppressed by light; ↑ at night → promotes sleep. Tryptophan → serotonin → N-acetylserotonin → melatonin (enzyme: AANAT, rate-limiting)
• Cortisol: Peak in early morning (6–8 AM); nadir at midnight. Circadian HPA axis regulation
• Core body temperature: Lowest at ~4 AM; highest at ~6 PM
• Sleep propensity: Two-process model, Process S (homeostatic sleep drive, adenosine accumulation) + Process C (circadian alerting signal from SCN)

C. Relevance to Psychiatry [5]

1. Major Depressive Disorder (MDD)

• Circadian abnormalities: Phase advance of circadian rhythms (early morning awakening, shortened REM latency, early cortisol rise)
• DST non-suppression: HPA axis circadian disruption, dexamethasone fails to suppress cortisol
• Sleep disturbances: Insomnia (most common), hypersomnia, early morning awakening
• Diurnal mood variation: Mood typically worst in morning (melancholic subtype)
• Seasonal Affective Disorder (SAD): Depression recurring in winter (reduced daylight) → phase delay of circadian rhythms → treated with bright light therapy (10,000 lux, 30 min in morning)

2. Bipolar Disorder

• Social Zeitgeber Theory (Ehlers): Disruption of social rhythms (sleep, meals, activity) destabilizes circadian rhythms → triggers mood episodes
• Mania: markedly reduced sleep need (not insomnia, patient doesn't feel tired)
• Depression: hypersomnia or insomnia
• Interpersonal and Social Rhythm Therapy (IPSRT), evidence-based psychotherapy stabilizing daily routines
• Dark therapy: Exposure to darkness/blue-light blocking glasses in evening → may reduce manic symptoms
• Clock gene polymorphisms (CLOCK, PER3, ARNTL) associated with bipolar susceptibility

3. Sleep Disorders

• Circadian rhythm sleep-wake disorders:
• Delayed sleep-wake phase disorder (DSWPD): Sleep onset and wake delayed by 2+ hours. Common in adolescents. Treatment: morning bright light + evening melatonin
• Advanced sleep-wake phase disorder (ASWPD): Early sleep onset and wake. Common in elderly. Treatment: evening bright light
• Non-24-hour sleep-wake disorder: Free-running rhythm (>24h). Common in blind individuals (no light entrainment). Treatment: tasimelteon (melatonin agonist)
• Shift work disorder: Misalignment between work schedule and circadian rhythm
• Jet lag disorder
• Irregular sleep-wake rhythm disorder

4. Schizophrenia

• Circadian disruption is nearly universal, sleep-wake fragmentation, reduced melatonin amplitude
• May contribute to cognitive dysfunction
• Clock gene variants associated with schizophrenia risk

5. ADHD

• Delayed circadian phase common (delayed melatonin onset)
• Sleep-onset insomnia highly prevalent
• Melatonin useful adjunct for sleep in ADHD

6. Chronotherapeutics, Therapeutic Applications:

Q21: "Functions of Pineal Gland.": 10 marks

A. Anatomy [1]

• Small (~8 mm), pine cone-shaped endocrine gland
• Located at the epithalamus, posterior to the third ventricle, between the superior colliculi
• Outside the blood-brain barrier (highly vascularized)
• Contains pinealocytes (produce melatonin) and glial cells
• Receives sympathetic innervation via a multisynaptic pathway: Retina → SCN → paraventricular nucleus (PVN) → intermediolateral cell column of spinal cord → superior cervical ganglion → pineal gland (norepinephrine release on beta-1 receptors stimulates melatonin synthesis)
• Calcifies with age ("brain sand"/corpora arenacea), visible on X-ray; shift indicates space-occupying lesion

B. Melatonin Synthesis and Regulation [3]

Synthesis pathway:

1. Tryptophan → (tryptophan hydroxylase) → 5-HTP → (AADC) → Serotonin
2. Serotonin → (arylalkylamine N-acetyltransferase, AANAT, rate-limiting, activated by NE via beta-1 → cAMP) → N-acetylserotonin
3. N-acetylserotonin → (hydroxyindole-O-methyltransferase, HIOMT) → Melatonin (N-acetyl-5-methoxytryptamine)

Regulation:

• Light INHIBITS melatonin production (light → retina → RHT → SCN → inhibits sympathetic output to pineal)
• Darkness STIMULATES melatonin (darkness → SCN disinhibits sympathetic pathway → NE release → beta-1 → cAMP → AANAT activation)
• Peak melatonin: 2–4 AM ("hormone of darkness")
• Secretion pattern: Low during day, rises in evening (dim light melatonin onset, DLMO, gold standard biomarker for circadian phase), peaks at night, falls by morning
• Metabolized by liver (CYP1A2) → 6-hydroxymelatonin → excreted as 6-sulfatoxymelatonin in urine (can measure to assess melatonin production)

Melatonin receptors:

• MT1 (Gi), promotes sleepiness, inhibits SCN firing
• MT2 (Gi), phase-shifts circadian rhythm
• MT3/quinone reductase, detoxification (less studied)
• Located in SCN, pars tuberalis of pituitary, retina, immune cells, various peripheral tissues

C. Functions of the Pineal Gland [4]

1. Circadian Rhythm Regulation (primary function)

• Melatonin is the endocrine signal of darkness
• Feeds back to SCN (MT1, MT2) to reinforce circadian timing
• Entrains peripheral clocks in liver, heart, immune cells
• DLMO is the most reliable marker of circadian phase

2. Sleep Regulation

• Melatonin promotes sleep onset, not a potent hypnotic but a chronobiotic (signals the brain that it is nighttime)
• Opens the "sleep gate" by reducing SCN-mediated alerting signal
• Exogenous melatonin: modestly effective for jet lag, DSWPD, elderly insomnia, pediatric sleep disorders (ADHD, ASD)

3. Seasonal/Reproductive Regulation

• In photoperiodic animals: melatonin duration signals day length → regulates seasonal breeding, coat changes
• In humans: less pronounced but melatonin influences puberty onset (pineal tumors → precocious puberty in some cases)
• Melatonin may modulate GnRH secretion

4. Antioxidant and Neuroprotection

• Melatonin is a potent free radical scavenger (directly neutralizes reactive oxygen and nitrogen species)
• Stimulates antioxidant enzymes (superoxide dismutase, glutathione peroxidase)
• Neuroprotective effects in neurodegeneration models (Alzheimer's, Parkinson's)
• ↓ Melatonin levels in Alzheimer's disease may contribute to sundowning and circadian disruption

5. Immune Modulation

• Melatonin enhances immune function: ↑ T-cell proliferation, ↑ NK cell activity, ↑ IL-2
• Immunosuppression seen with chronic melatonin deficiency (elderly, pinealectomy)
• Anti-inflammatory properties, reduces pro-inflammatory cytokines

6. Thermoregulation

• Melatonin promotes heat loss (peripheral vasodilation) → core body temperature drops → facilitates sleep onset
• Circadian temperature rhythm linked to melatonin secretion

7. Anti-tumor Properties

• Epidemiological: night shift workers (suppressed melatonin) have ↑ risk of breast and colorectal cancer
• Melatonin: anti-proliferative, pro-apoptotic effects in cancer cell lines
• WHO: "shift work involving circadian disruption is a probable carcinogen (Group 2A)"

D. Clinical Relevance [2]

SECTION C: SLEEP PYQs (Q22–Q27)

Q22: "Physiology of sleep.": 10 marks

A. Introduction and Two-Process Model [2]

Sleep is a reversible state of reduced consciousness and responsiveness, actively generated by the brain, essential for physiological restoration.

Borbely's Two-Process Model of Sleep Regulation:

Sleep occurs when Process S is high AND Process C alerting signal is low (typically at night).

B. Stages of Sleep [3]

Sleep is classified by polysomnography (PSG): EEG + EOG + EMG

AASM (American Academy of Sleep Medicine) Classification:

Sleep architecture:

• Sleep cycles: 4–6 cycles per night, each ~90–110 minutes (ultradian rhythm)
• Early night: More SWS (N3)
• Late night: More REM sleep (REM periods lengthen across the night)
• REM latency: ~90 minutes from sleep onset (shortened in depression, narcolepsy)

C. Neurobiology of Sleep-Wake Regulation [3]

Wake-Promoting Systems (ascending arousal system):

Sleep-Promoting Systems:

Flip-Flop Switch Model (Saper):

• VLPO (sleep) and arousal nuclei (wake) are mutually inhibitory
• System is bistable, either fully awake or fully asleep (prevents intermediate states)
• Orexin stabilizes the switch on the wake side → without orexin, switch is unstable → inappropriate transitions into sleep (narcolepsy with cataplexy)

REM-Sleep Regulation:

• REM-on neurons: LDT/PPT (cholinergic), generate REM features
• REM-off neurons: LC (NE) and DRN (5-HT), suppress REM. These go silent during REM.
• Subcoeruleus/sublaterodorsal nucleus: Generates REM atonia via inhibitory projections to spinal motor neurons (glycinergic/GABAergic)
• REM without atonia → REM sleep behavior disorder (RBD), acts out dreams. Preclinical marker for alpha-synucleinopathies (Parkinson's, DLB)

D. Functions of Sleep [2]

(See Q23 for neurobiology focus, Q24 for expanded stage detail, Q25 for clinical applications)

Q23: "Neurobiology of sleep and wakefulness.": 10 marks

A. Ascending Arousal System (Wakefulness) [3]

Two branches of the ascending reticular activating system (ARAS):

Branch 1: Dorsal pathway (thalamic relay)

• LDT/PPT (ACh) → thalamus → cortex
• Enables thalamocortical transmission → EEG desynchronization (wakefulness)

Branch 2: Ventral pathway (extrathalamic)

• LC (NE), DRN (5-HT), TMN (histamine), lateral hypothalamus (orexin), basal forebrain (ACh), vPAG (DA) → directly to cortex and subcortical structures
• Provides diffuse cortical activation

Orexin/Hypocretin System (Key stabilizer):

• ~70,000 neurons in lateral hypothalamus
• Two peptides: Orexin A (OX-A) and Orexin B (OX-B)
• Two receptors: OX1R (binds OX-A preferentially) and OX2R (binds both equally)
• Projects widely to LC, DRN, TMN, basal forebrain, VTA
• Function: Stabilizes the flip-flop switch on the wake side; promotes sustained wakefulness; links wake to reward, feeding, stress
• Loss of orexin neurons: Narcolepsy type 1 (with cataplexy). CSF orexin < 110 pg/mL is diagnostic.

B. Sleep-Promoting System (NREM Sleep) [2]

VLPO (Ventrolateral Preoptic Area):

• Contains GABAergic and galaninergic neurons
• Active during sleep → inhibits LC, DRN, TMN, orexin neurons
• VLPO lesion (in rats) → 70% reduction in sleep
• Activated by: adenosine (A2A receptors), cytokines (IL-1, TNF-α), prostaglandin D2, warming

Adenosine:

• By-product of ATP metabolism → accumulates during prolonged wakefulness
• Acts on A1 receptors (inhibits wake-promoting neurons) and A2A receptors (activates VLPO)
• Caffeine blocks A1/A2A → promotes wakefulness
• This mediates Process S (homeostatic sleep drive)

Melatonin:

• MT1: inhibits SCN firing → reduces alerting signal
• MT2: shifts circadian phase
• Does not directly induce sleep but facilitates the transition (opens "sleep gate")

C. Flip-Flop Switch Model [2]

(See Q22 Section C for description)

• Wake side: LC, DRN, TMN, orexin (mutually reinforcing)
• Sleep side: VLPO (GABA/galanin)
• Mutual inhibition → bistable switch → sharp transitions
• Orexin stabilizes wake side → prevents unwanted sleep intrusions
• Narcolepsy = destabilized switch → state instability (sudden REM intrusions, cataplexy, sleep attacks, hypnagogic hallucinations, sleep paralysis)

Diagram description: Draw two boxes (VLPO on left, arousal nuclei on right) with mutually inhibitory arrows (GABA from VLPO, monoamines from arousal side). Orexin arrow reinforcing the arousal side. Label: orexin loss → destabilized switch → narcolepsy.

D. REM Sleep Neurobiology [2]

REM-on:

• LDT/PPT (cholinergic): Generate REM features, cortical activation, PGO waves, rapid eye movements
• Subcoeruleus nucleus (SLD/SubC): Generates REM atonia (glutamate → ventral medullary inhibitory neurons → glycine/GABA onto spinal motor neurons)

REM-off:

• LC (NE) and DRN (5-HT): Active during wake, progressively less active through NREM, completely silent during REM
• vPAG (GABAergic): Inhibits SLD during wakefulness

REM regulation:

• Reciprocal interaction model (Hobson & McCarley): Aminergic REM-off and cholinergic REM-on neurons oscillate reciprocally
• During NREM → aminergic tone gradually decreases → cholinergic neurons become disinhibited → REM begins
• REM atonia failure → REM sleep behavior disorder (RBD) → dream enactment → alpha-synucleinopathy risk (>80% develop PD/DLB within 15 years)

E. Pharmacological Correlates [1]

Q24: "Define sleep. Describe stages of sleep. Discuss physiology of sleep.": 10 marks

A. Definition [1]

Sleep is a naturally recurring, readily reversible state of reduced consciousness, decreased motor activity, and diminished responsiveness to external stimuli, actively generated by specific brain circuits. It is distinguished from coma and anesthesia by its reversibility and from quiet wakefulness by its reduced awareness.

Characteristics: Reduced consciousness, stereotypic posture, decreased reactivity to stimuli, reversibility, cyclic recurrence (circadian), homeostatic regulation (sleep debt accumulates).

B. Stages of Sleep [4]

Measured by polysomnography (PSG):

• EEG: Brain electrical activity
• EOG (electrooculography): Eye movements
• EMG (electromyography): Muscle tone (submental/chin)

NREM Sleep (Non-Rapid Eye Movement), 75–80% of total sleep:

REM Sleep, 20–25% of total sleep:

Sleep cycle progression:

N1 → N2 → N3 → N2 → REM → (repeat)

• Cycle length: ~90-110 minutes
• 4-6 cycles per night
• First third of night: SWS dominant
• Last third of night: REM dominant

C. Physiology of Sleep [5]

(Combines key elements from Q22 and Q23)

1. Two-Process Model:

• Process S (homeostatic) + Process C (circadian), see Q22 Section A

2. Wake-Sleep Switch (Saper's Flip-Flop):

• VLPO (GABA/galanin) ↔ arousal nuclei (LC/DRN/TMN/orexin), mutually inhibitory
• Orexin stabilizes wakefulness

3. NREM generation:

• VLPO activation → inhibits arousal nuclei → cortical deactivation
• Thalamocortical oscillations generate sleep spindles (N2) and delta waves (N3)
• Thalamic reticular nucleus: pacemaker for spindle generation

4. REM generation:

• LDT/PPT (cholinergic) → REM-on
• LC/DRN silent during REM → REM-off neurons cease
• Subcoeruleus → spinal inhibition → atonia
• PGO waves: ponto-geniculo-occipital spikes → visual imagery in dreams

5. Hormonal changes during sleep:

(Cross-reference: Q22 for functions, Q23 for neurobiology detail, Q25 for clinical applications)

Q25: "Describe in detail about various types of sleep disorders in general psychiatry practice and discuss how a disturbance in sleep architecture can be used as a diagnostic tool.": 10 marks

A. Classification of Sleep Disorders (ICSD-3) [3]

1. Insomnia Disorders

• Chronic insomnia disorder: Difficulty initiating/maintaining sleep or early morning awakening, ≥3 nights/week, ≥3 months, with daytime impairment. Most common sleep complaint in psychiatry.
• Short-term insomnia: < 3 months
• Comorbid with: depression (80%), anxiety (70%), PTSD, substance use

2. Sleep-Related Breathing Disorders

• Obstructive Sleep Apnea (OSA): Recurrent upper airway collapse during sleep → apneas/hypopneas → oxygen desaturation → arousals. AHI ≥5 with symptoms or AHI ≥15. Psychiatric relevance: comorbid depression, cognitive impairment, treatment-resistant depression (screen for OSA), ADHD-like symptoms, psychosis (severe sleep deprivation).
• Treatment: CPAP, weight loss, mandibular advancement device

3. Central Disorders of Hypersomnolence

• Narcolepsy Type 1: Excessive daytime sleepiness + cataplexy + low CSF orexin (<110 pg/mL). Also: sleep paralysis, hypnagogic hallucinations, disrupted nocturnal sleep
• Narcolepsy Type 2: EDS without cataplexy, normal CSF orexin
• Idiopathic hypersomnia: EDS with prolonged sleep, sleep inertia ("sleep drunkenness")
• Kleine-Levin syndrome: Recurrent hypersomnia (days-weeks) + cognitive/behavioral disturbance (hyperphagia, hypersexuality, derealization). Primarily adolescent males.

4. Circadian Rhythm Sleep-Wake Disorders

• Delayed sleep-wake phase, advanced phase, non-24-hour, shift work, jet lag, irregular rhythm

5. Parasomnias

6. Sleep-Related Movement Disorders

• Restless legs syndrome (RLS), periodic limb movement disorder (PLMD)
• (See Q27 for PLMD detail)

B. Sleep Architecture as a Diagnostic Tool [4]

Key principle: Specific psychiatric disorders produce characteristic polysomnographic signatures.

Specific diagnostic applications:

• MSLT (Multiple Sleep Latency Test): For narcolepsy diagnosis, measures how quickly patient falls asleep and whether SOREMPs occur during 5 daytime nap opportunities
• MWT (Maintenance of Wakefulness Test): Ability to stay awake, used for fitness-to-drive assessments
• Actigraphy: Wrist-worn accelerometer; 1-2 week recording for circadian rhythm disorders, insomnia evaluation

C. Management Principles [3]

Q26: "Disorders of Sleep wake cycle.": 10 marks

A. Circadian Rhythm Sleep-Wake Disorders (CRSWD) [5]

Underlying mechanism: Misalignment between the endogenous circadian clock (SCN) and the desired/required sleep-wake schedule.

1. Delayed Sleep-Wake Phase Disorder (DSWPD)

• Description: Habitual sleep onset and wake times delayed by ≥2 hours relative to conventional times
• Prevalence: 7-16% of adolescents/young adults
• Features: Cannot fall asleep until 2-6 AM; cannot wake until 10 AM-12 PM. Normal sleep quality/duration when allowed to sleep on own schedule. Chronic insomnia (sleep-onset type) and excessive morning sleepiness when forced to conventional schedule
• Diagnosis: Sleep diary + actigraphy for ≥7 days; DLMO delayed
• Treatment:
• Morning bright light (10,000 lux, 30 min upon waking) → phase advances circadian clock
• Evening melatonin (0.5-3 mg, 4-6 hours before desired sleep) → advances clock
• Chronotherapy (progressively delay sleep time by 2-3 hours/day until desired time reached, rarely used, difficult compliance)
• Avoid evening screens/blue light

2. Advanced Sleep-Wake Phase Disorder (ASWPD)

• Description: Sleep onset and wake times advanced by ≥2 hours (e.g., sleeps 6 PM, wakes 2 AM)
• Prevalence: Common in elderly. Familial form (CK1delta/PER2 mutations)
• Treatment: Evening bright light (delays clock); avoid morning bright light

3. Non-24-Hour Sleep-Wake Disorder (Free-Running)

• Description: Sleep-wake cycle progressively drifts later each day (~24.2 hour period) because the endogenous clock is not entrained to the 24-hour light-dark cycle
• Prevalence: >50% of totally blind individuals (no light entrainment via melanopsin/RHT)
• Features: Cyclical periods of good sleep (when rhythm aligns with desired schedule) and poor sleep (when misaligned)
• Treatment: Tasimelteon (Hetlioz, FDA-approved), MT1/MT2 agonist; melatonin

4. Shift Work Disorder

• Description: Insomnia and/or excessive sleepiness due to work schedule overlapping normal sleep period
• Features: Night/rotating shift workers. ↑ Risk of metabolic syndrome, cardiovascular disease, depression, GI problems, accidents, cancer (WHO Group 2A carcinogen)
• Treatment: Strategic napping, caffeine before shift, bright light during shift, dark glasses on commute home, melatonin for daytime sleep, modafinil for sleepiness during shift

5. Jet Lag Disorder

• Description: Temporary misalignment after rapid transmeridian travel
• Features: Insomnia, daytime sleepiness, GI disturbance, malaise. Eastward travel worse (requires phase advance, harder). ~1 day per time zone to adapt
• Treatment: Timed light exposure and melatonin; short-acting hypnotics

6. Irregular Sleep-Wake Rhythm Disorder

• Description: No clear circadian rhythm; multiple short sleep bouts across 24 hours
• Features: Common in neurodegenerative diseases (Alzheimer's, dementia, SCN degeneration), institutionalized elderly, developmental disabilities
• Treatment: Structured light exposure, social scheduling, melatonin

B. Other Sleep-Wake Cycle Disorders [5]

1. Narcolepsy Type 1 (with cataplexy)

• Loss of orexin neurons → destabilized sleep-wake switch
• Pentad: Excessive daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by emotion), sleep paralysis, hypnagogic/hypnopompic hallucinations, disrupted nocturnal sleep
• Diagnosis: MSLT (mean latency <8 min + ≥2 SOREMPs) + low CSF orexin
• Treatment: Modafinil/armodafinil (EDS), sodium oxybate/oxybate salts (cataplexy + sleep consolidation), solriamfetol, pitolisant

2. Narcolepsy Type 2 (without cataplexy)

• EDS with ≥2 SOREMPs on MSLT but no cataplexy, normal CSF orexin

3. Idiopathic Hypersomnia

• EDS with prolonged nighttime sleep (>11 hours) and/or prolonged unrefreshing naps
• Severe sleep inertia ("sleep drunkenness")
• MSLT: mean latency <8 min, <2 SOREMPs (distinguishes from narcolepsy)
• No cataplexy, normal orexin
• Treatment: Modafinil, FDA-approved: lower-sodium oxybate (Xywav)

4. Kleine-Levin Syndrome

• Rare; primarily adolescent males
• Recurrent episodes (days-weeks) of hypersomnia + cognitive/behavioral disturbance (hyperphagia, hypersexuality, derealization, apathy)
• Between episodes: normal sleep and behavior
• Etiology: likely autoimmune/hypothalamic
• Treatment: Lithium (prophylaxis); stimulants (during episodes)

5. Sleep-Wake Cycle Disruption in Psychiatric Disorders

Q27: "Periodic limb movement disorders in sleep.": 10 marks

A. Definition and Clinical Features [2]

Periodic Limb Movement Disorder (PLMD) is a sleep disorder characterized by repetitive, stereotyped limb movements (usually lower extremities) that occur during sleep, causing sleep fragmentation and daytime consequences.

Movement characteristics:

• Extension of big toe + dorsiflexion of ankle ± flexion of knee and hip (triple flexion response)
• Duration: 0.5–10 seconds per movement
• Occur in periodic clusters at intervals of 5–90 seconds (typically 20–40 seconds)
• Primarily during NREM sleep (especially N1 and N2); less in SWS; absent in REM (due to atonia)
• Patient is usually unaware; bed partner often reports kicking

Consequences:

• Recurrent arousals → fragmented sleep → unrefreshing sleep
• Excessive daytime sleepiness
• Insomnia (difficulty maintaining sleep)

Epidemiology:

• Prevalence increases with age: 4-11% of adults; up to 45% of elderly (>65 years)
• M = F (or slight male predominance)
• >80% of patients with RLS also have PLMs, but PLMD can occur independently

B. PLMD vs. Restless Legs Syndrome (RLS): Key Distinction [2]

PLMS vs. PLMD:

• PLMS (Periodic Limb Movements of Sleep): The PSG finding. Common incidental finding, especially in elderly. Not a disorder unless causing clinical consequences.
• PLMD: PLMS + clinical consequences (insomnia, excessive daytime sleepiness) + no better explanation (no RLS, OSA, narcolepsy, medication effect).

C. Pathophysiology [2]

1. Iron-Dopamine Hypothesis (shared with RLS):

• Brain iron deficiency (even with normal serum ferritin) → impaired dopamine synthesis (iron is cofactor for tyrosine hydroxylase)
• Reduced dopaminergic inhibition of spinal cord motor neurons → periodic leg movements
• Supportive evidence: Low CSF ferritin in PLMD/RLS; MRI shows ↓ iron in substantia nigra and thalamus; dopamine agonists are effective treatment
• Serum ferritin <50 ng/mL (some guidelines <75) → warrants iron supplementation

2. Spinal cord excitability:

• PLMs resemble the Babinski response (triple flexion withdrawal)
• Suggests disinhibition of spinal flexor reflex pathways during sleep
• May involve descending dopaminergic, serotonergic, and noradrenergic pathway dysfunction

3. Circadian component:

• PLMs and RLS symptoms both show circadian variation (worse in evening/night)
• Brain iron is lowest in evening → dopamine synthesis lowest → symptoms worst
• Melatonin may modulate dopamine release (complex interaction)

4. Associated conditions:

D. Diagnosis [2]

Polysomnographic criteria (AASM):

• PLM definition: Leg movements lasting 0.5-10 seconds, occurring in series of ≥4 consecutive movements, with inter-movement intervals of 5-90 seconds
• PLMI (Periodic Limb Movement Index): Number of PLMs per hour of sleep
• Clinically significant: PLMI ≥15/hour in adults (≥5/hour in children)
• PLMAI (PLM Arousal Index): PLMs associated with EEG arousals; >5/hour considered significant

Diagnostic workup:

• PSG: Required for PLMD diagnosis (but not for RLS, clinical)
• Serum ferritin: Check in all patients. Target >50-75 ng/mL (some experts: >100)
• Iron studies: Serum iron, TIBC, transferrin saturation
• Renal function: Rule out CKD/ESRD
• Exclude other conditions: OSA (can cause PLMs), narcolepsy, medications
• Leg EMG (anterior tibialis): Bilateral recording during PSG

E. Treatment [2]

1. Address modifiable causes:

• Iron supplementation: If ferritin <50-75 ng/mL → oral ferrous sulfate 325 mg + vitamin C (enhances absorption) on empty stomach. If oral fails or ferritin <30 → IV iron (ferric carboxymaltose)
• Discontinue/substitute offending medications: SSRIs/SNRIs → consider bupropion (does not worsen; may help); switch antipsychotic

2. Pharmacotherapy:

3. Augmentation (key concept):

• Most important long-term complication of dopaminergic treatment
• Features: symptoms begin earlier in the day, intensity increases, spread to upper limbs, reduced efficacy
• Management: taper dopamine agonist, switch to alpha-2-delta ligand, check and treat iron deficiency
• Prevention: use lowest dose, prefer alpha-2-delta ligands as first-line, maintain ferritin >75 ng/mL

4. Non-pharmacological:

• Sleep hygiene
• Regular moderate exercise (not close to bedtime)
• Avoidance of caffeine, alcohol, nicotine
• Compression stockings, leg massage, warm baths (some benefit for RLS; less evidence for PLMD specifically)

QUICK REFERENCE: TOP 5 LONG ESSAY CANDIDATES

CROSS-REFERENCE MAP

Mnemonics & Memory Tricks

1. Dopamine Pathways

🔖 Mnemonic: "MeMe NiTu"

Encodes: The four major dopamine pathways

Expansion:

Swipe to compare →

Why this works: Four syllables, two letters each, maps 1:1 to four pathways with no ambiguity.

🆕 Alternate mnemonic (clinical correlation): "Meso Rewards, Meso Thinks, Nigro Moves, Tubero Milks"

Expansion:

• Mesolimbic rewards → pleasure, motivation, positive symptoms
• Mesocortical thinks → working memory, planning, negative/cognitive symptoms
• Nigrostriatal moves → voluntary motor control, EPS when blocked
• Tuberoinfundibular milks → prolactin inhibition, galactorrhoea when blocked

2. Serotonin Receptor Subtypes

🆕 Mnemonic: "1A Anxious, 1B Brakes migraine, 2A Sees things, 2C Craves food, 3 Throws up, 4 Gut moves, 6 Sleeps, 7 Clocks"

Encodes: Primary function of each major 5-HT receptor subtype

Expansion:

🆕 Bonus: Atypical Antipsychotics' Serotonin Trick: "2A block = Atypical"

3. Serotonin Syndrome

🔖 Mnemonic: "HOT: Hyperactive muscles, Overactive reflexes, Tremor/Temperature"

Expansion:

1. Neuromuscular hyperactivity, clonus (spontaneous, inducible, ocular), hyperreflexia, rigidity, tremor
2. Autonomic dysfunction, hyperthermia, tachycardia, diaphoresis, diarrhoea, mydriasis
3. Mental status changes, agitation, confusion, hypomania

🔖 Hunter Criteria (diagnostic): "CATCH IT"

Expansion:

• Clonus (spontaneous) → diagnostic
• Agitation + inducible clonus
• Tremor + hyperreflexia
• Clonus (inducible) + diaphoresis
• Hypertonia + temperature >38°C + ocular clonus
• Inducible clonus (ocular) + agitation/diaphoresis
• Temperature >38°C + ocular clonus

🆕 Serotonin Syndrome vs NMS Differentiator: "Serotonin is FAST, NMS is SLOW"

4. Basal Ganglia Components

🆕 Mnemonic: "CPU-SS" 🏏

Encodes: Five major components of the basal ganglia

Expansion:

• C = Caudate nucleus
• P = Putamen
• U = Globus pallidus (GPe + GPi)
• S = Subthalamic nucleus (STN)
• S = Substantia nigra (SNc + SNr)

Why this works: CPU processes commands, the basal ganglia processes motor commands. Two S's at the end for the two "sub-" structures.

Key groupings to remember:

🆕 Direct vs Indirect Pathway: "Direct = Do it, Indirect = Inhibit it"

• Direct pathway (cortex → striatum → GPi/SNr → thalamus → cortex): Net effect = facilitates movement. Think "D2 receptor dysfunction" in indirect, but the D1 receptor drives the direct path.
• Indirect pathway (cortex → striatum → GPe → STN → GPi/SNr → thalamus → cortex): Net effect = suppresses movement.
• Dopamine from SNc excites direct (D1) and inhibits indirect (D2) → net effect: MORE movement. Loss of dopamine (Parkinson's) = less movement.